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ABSTRACT OF THE DISSERTATION 
 
Structural Studies of Pathogenic Amyloids 
by 
 
Smriti Sangwan 
Doctor of Philosophy in Molecular Biology 
University of California, Los Angeles, 2017 
Professor David S. Eisenberg, Chair 
 
 
My research project is focused on deciphering the structural basis of toxicity in 
neurodegenerative diseases including Parkinson’s and Lou Gehrig’s (ALS) disease. Even though 
large proteinacious deposits that are amyloid in nature are found in these diseases, scientific 
evidence in recent years has tilted the opinion in favor of small oligomers as the more toxic 
species. However, the transient nature of these small oligomers has made their study extremely 
difficult. The Eisenberg lab has focused on characterizing amyloid aggregates from a structural 
perspective. We have deciphered the atomic resolution structure of segments from these proteins 
in their amyloid-like conformation and used the structures to design inhibitors that prevent 
aggregation. We have now focused on characterizing these transient oligomers. In my research, I 
have worked on two amyloid-forming proteins namely Superoxide Dismutase 1 (SOD1) and 
Alpha Synuclein (α-syn) and have attempted to understand the basis of their toxicity. My results 
suggest two different modes of action for these proteins. For SOD1, moderately sized oligomers 
 iii 
seem to be more toxic than insoluble amyloid aggregates, but for α-syn the fibers are more toxic. 
Using the atomic structure of the spine of α-syn fibrils, I have developed a new line of inhibitors 
that prevent fibril growth and propagation. My results reveal a novel therapeutic approach 
targeted at the spread and progression that may be applicable for PD and related 
synucleinopathies.
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1 
Introduction and Dissertation Layout 
Neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Lou Gehrig’s (ALS) are 
characterized by loss of neuronal cells, which leads to dementia, motor defects and ultimately 
death. These diseases are fatal and current treatment options are limited. Furthermore, with a 
global aging population they also present a huge financial burden on our health care system and 
emotional burden on caregivers. In all of these diseases, aggregated proteins – α-synuclein in 
Parkinson’s, amyloid-β in Alzheimer’s and SOD1 in ALS are found. Why these proteins 
aggregate and the structure of the toxic entity has been unknown until now. The Eisenberg lab 
has focused on characterizing amyloid aggregates from a structural perspective. We have 
deciphered the atomic resolution structures of segments from these proteins in their amyloid-like 
conformation and used the structures to design inhibitors that prevent aggregation. In my 
research, I have worked on two amyloid-forming proteins namely Superoxide Dismutase 1 
(SOD1) and Alpha Synuclein (α-syn). My results suggest two different modes of action for these 
proteins. For SOD1, soluble oligomers seem to be more toxic than insoluble aggregates, but for 
α-syn the large aggregates are more toxic. 
 
Dissertation Layout 
Chapter 1 is a reprint of a review article published in 2016. In this review, we summarize the 
various hypotheses presented for the mechanism of SOD1-mediated motor neuron death in ALS. 
We discuss the different structural and biochemical studies performed on SOD1 and its familial 
mutants. I thank David Eisenberg for his help in writing this review. 
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Chapter 2 is a draft of the manuscript currently in submission for publication. In this work, we 
identified a short segment, 28-38 of SOD1 that is both necessary and sufficient for cytotoxicity. 
We discovered that the segment is important for oligomer formation but not for fibril formation. 
We also determined the atomic structure of this segment, which revealed an oligomer composed 
of anti-parallel β-strands forming a twisted sheet structure termed corkscrew. Using mutagenesis 
and biochemical assays, we showed that the integrity of the structure is critical for SOD1-
mediated cytotoxicity. I thank Anni Zhao for help with experiments, Albert Pan and David Shaw 
for performing the computational simulations, Michael Sawaya for help with solving the 
structure, Katrina Adams and Destaye Moore for assistance with motor neuron culture, Christina 
Jayson, Jennifer Ngo and Carla Koehler for zebrafish experiments, Elizabeth Guenther and 
Angela Soriaga for biochemical assays, Anand Panchal and Mark Geisburg for antibody 
generation and Lukasz Goldshmidt and Rebecca Nelson for performing the computational 
predictions, and Bennett Novitch and David Eisenberg for help with experimental design and 
manuscript preparation. 
 
Chapter 3 is a manuscript in preparation in which we build on our discovery of the corkscrew. 
We obtained three new atomic resolution structures of variants of the corkscrew-forming 
segment; a corkscrew-like structure, pairs of untwisted highly curved sheets and a steric zipper 
proto-filament structure. These results suggest that the segment has a high propensity to form 
corkscrew-like structures and the twisted sheet structure is important for cytotoxicity. I thank 
Michael Sawaya for help with solving the crystal structures, Kevin Murray for performing the 
computational predictions and Michael Hughes for help with fiber diffraction. 
 
 3 
Chapter 4 is a manuscript in preparation. In this work, we developed a line of inhibitors that 
prevent α-syn aggregation. The small peptidic inhibitors were designed against the structure of a 
short segment of α-syn. Using biochemical and cell culture models of seeding, I tested the 
efficacy of the inhibitors and found them to effectively prevent α-syn aggregation and spread. 
These results reveal a novel therapeutic approach targeted at the prion-like spread of α-syn 
aggregates. I thank Lin Jiang and Kevin Murray for help with computational predictions, Shruti 
Sahay for help with biochemical assays and Michel Goedert for advice and suggestions.  
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 Chapter 1: Perspective on SOD1 mediated toxicity in Amyotrophic Lateral Sclerosis 
 
This chapter is a reprint of: 
Perspective on SOD1 mediated toxicity in Amyotrophic Lateral Sclerosis. 
Sangwan S, Eisenberg DS. 
Postepy Biochem. 2016;62(3):362-369. Review. 
 
Abstract: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized 
by the progressive degeneration of spinal motor neurons. Although mutations in dozens of 
proteins have been associated with ALS, the enzyme, superoxide dismutase 1 (SOD1) was the 
first protein identified with the development of ALS and accounts for ~20% of familial cases. In 
experimental animals and patient samples, mutant SOD1 is found in cytoplasmic deposits 
implicating SOD1 aggregates as the toxic entities. Here we discuss the various biochemical and 
structure-based hypotheses proposed for mutant SOD1-associated ALS. Although much remains 
to be discovered about the molecular mechanism of SOD1 mediated toxicity, these hypotheses 
offer new avenues for therapeutic development. 
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Perspective on SOD1 mediated toxicity in Amyotrophic Lateral Sclerosis*
ABSTRACT
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive degeneration of spinal motor neurons. Although mutations in dozens of 
proteins have been associated with ALS, the enzyme, superoxide dismutase 1 (SOD1) was 
the first protein identified with the development of ALS and accounts for ~20% of familial 
cases. In experimental animals and patient samples, mutant SOD1 is found in cytoplasmic 
deposits implicating SOD1 aggregates as the toxic entities. Here we discuss the various bio-
chemical and structure-based hypotheses proposed for mutant SOD1-associated ALS. Al-
though much remains to be discovered about the molecular mechanism of SOD1 mediated 
toxicity, these hypotheses offer new avenues for therapeutic development.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a late-adult onset disease characterized 
by the loss of voluntary motor functions. Patients live an average of 3-5 years 
after the appearance of symptoms and very few are known to have survived 
for more than two decades [1]. Clinically the disease is identified by loss of mo-
tor function, which progresses in an unusually fast and unpredictable manner. 
Proteinaceous deposits are found in degenerating motor neurons of the cerebel-
lum, cortex and spinal cord suggesting that protein aggregation is the under-
lying cause of the disease. Although 90% of all ALS cases are sporadic (sALS), 
5–10% of cases are inherited and called familial ALS (fALS); these have a clear 
genetic linkage to a specific gene. Genome-wide association studies (GWAS) in 
the last decade have implicated nearly 30 genes in ALS pathogenesis. Of these, 
the majority code for the proteins TARDP, SOD1, FUS, VCP and OPTN (Fig. 
1). The gene encoding the cytosolic enzyme, superoxide dismutase 1 (SOD1) 
was first discovered to have mutations in ALS patients in 1993 [2]. Mutations in 
the SOD1 gene are found in the exons suggesting that their toxic effects are the 
result of malfunctions of the protein. Furthermore, large aggregates that stain 
as SOD1 are found in autopsy samples suggesting a pathological link between 
SOD1 aggregates and motor neuron death. The role of SOD1 in sporadic and 
non-SOD1 linked fALS is less clear. Biochemical studies and antibody reactivity 
suggest an altered SOD1 conformation is present in both sALS and non-SOD1-
linked fALS patients [3–5]. SOD1 aggregates are also observed in the presence of 
mutant TDP-43 and FUS in patients and in cell culture suggesting cross talk be-
tween various proteins associated with ALS [6]. An oxidized form of wild-type 
SOD1 (wtSOD1) has also been detected in sporadic patient tissues [7]. Recently, 
Figure 1. Different ALS-linked genes classified by function.
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mutations in SOD1 were also found in sporadic forms of 
ALS such as the aggressive juvenile-onset ALS [8,9]. From 
these reports it appears that SOD1 plays a role that extends 
to ALS cases associated with mutations in other proteins, as 
well as to at least some sporadic cases. To date more than 
160 different disease-associated mutations have been found 
in SOD1; these are spread over the entire 153 amino acid 
sequence (http://alsod.iop.kcl.ac.uk). Studies over the last 
two decades have elucidated key features of mutant SOD1 
(mSOD1) aggregation. It is generally accepted that mSOD1 
acquires toxic properties: mSOD1 does not lose its enzymat-
ic activity [10] and knockdown of wild-type SOD1 does not 
cause ALS symptoms in mice [11]. Together these observa-
tions strengthen the hypothesis that disease mutations con-
fer a toxic function that ultimately causes cellular dysfunc-
tion.
In this review, we summarize the various hypotheses 
proposed for mSOD1 toxicity. We focus on the biophysical 
studies of SOD1 mutants, and in particular the biochemical 
and structural data that suggest varying roles for different 
regions of the SOD1 protein in aggregation and ALS patho-
genesis.
STRUCTURAL MODELS FOR 
CHANGES IN MUTANT SOD1
Several proteins associated with neurodegenerative 
diseases such as β-amyloid, α-synuclein and islet amyloid 
polypeptide do not have a native tertiary structure. How-
ever, SOD1 does have a tertiary structure and the effect of 
mutations on the native structure has been extensively stud-
ied. The native metal-bound SOD1 exists as a homo-dimer 
wherein each monomer has a Greek key architecture and 
binds one copper and one zinc ion (Fig. 2A). The monomer 
is composed of an eight-stranded β barrel and two loops – 
the metal binding loop (spanning residues 49-84) and the 
electrostatic loop (spanning residues 122-143) [12,13]. The 
simplest hypothesis for mutant SOD1-mediated neuro-
nal damage is that the presence of each disease mutation 
increases the aggregation propensity of the protein. These 
aggregates accumulate over time and are toxic to neuronal 
cells. In support of this hypothesis, severity of the disease 
correlates with the aggregation propensity of the mutants. 
For example, patients with the A4V mutation survive only 
6 months post symptom-onset and this mutation increases 
the aggregation propensity many fold. However, the in-
crease in aggregation propensity does not correlate with 
an earlier age of disease onset [14,15]. Furthermore, not all 
disease mutations increase the aggregation propensity of 
the protein [14] (Table 1). Structural studies of more than 
a dozen different SOD1 constructs harboring disease-relat-
ed mutations have been carried out and provide conflicting 
results. Overall, most mutations do not cause major struc-
tural alterations to the native SOD1 structure [16]. Crystal 
structures of A4V and I113T mutants show some structural 
deviations in the dimer interface that might contribute to 
increased aggregation propensity [17] and the structure of 
the G37R mutant shows altered subunit arrangement [18] 
while structures of D124V and H80R mutants show disrupt-
ed metal binding loops [19]. Mutations such as A4V, G93A, 
I113T and G37R also do not affect the enzymatic activity 
of the protein whereas G85R and H48Q mutations that are 
present in the metal binding loop lead to reduced activi-
ty [16]. In light of these conflicting reports, it is difficult to 
determine if increased aggregation propensity is the only 
effect of mutations that cause the disease; whereas protein 
aggregation may contribute to disease progression, it may 
not be the cause of the disease itself.
Another hypothesis is that the mutations introduce struc-
tural instability either by destabilizing the native structure 
or by reducing its metal binding affinity [20]. One line of 
evidence supporting this hypothesis is that large molecular 
weight aggregates are seen prior to disease onset in trans-
genic mice [21,22]. Additionally, large inclusion bodies con-
taining insoluble SOD1 are found only in end-stage mice 
[23,24]. Biochemical and cell culture studies also show that 
SOD1 forms soluble oligomers that are sufficient to cause 
toxicity [25–29]. In-cell NMR and mutagenesis studies have 
shown that several mutants lack metal binding and are 
prone to oligomerization [30]. Structural studies of metal 
Figure 2. A) Crystal structure of metal-bound SOD1 (PDB 2C9S). Native SOD1 
exists as a stable dimer. Each monomer is composed of an eight-stranded β barrel 
(red) and a metal binding loop (magenta) and an electrostatic loop. Cu and Zn 
are shown respectively as yellow and blue spheres. Strands facing towards the 
viewer are named in black and away from the viewer are named in gray. B) Wild 
type SOD1 is an exceptionally stable dimer and can be monomerized only by loss 
of metal ions. C) A disease mutation (blue cross) can gain a toxic function by dif-
ferent modes. It can increase the propensity to monomerize and these monomers 
in turn can form oligomers with non-native quaternary structure that may be tox-
ic. Another mode of oligomerization involves apo dimers that harbor non-native 
contacts forming fibrous assemblies.
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depleted mutants also support this hypothesis. For exam-
ple, in the crystal structures of the metal deficient mutants 
– H46R, S134N, D124V and H80R significant new inter-mol-
ecule interfaces are observed [19,31–33]. The buried surface 
area in these new interactions is identical to the native di-
meric interface and thus proposed to be significant. Further-
more, these new interfaces can only occur by rearranging 
the metal binding loop. Therefore, reduced metal binding 
would increase flexibility and in principle stabilize these in-
teractions. However, it is important to note that these inter-
actions are observed only in the crystal structures and their 
physiological relevance has been unclear.
In addition to studies investigating the effect of dis-
ease-linked mutations on the global structure of SOD1, re-
search groups have analyzed the SOD1 protein sequence to 
identify segments that affect the aggregation kinetics. Ag-
gregates isolated from the spinal cords of transgenic mice 
have been shown to contain full-length SOD1 that is devoid 
of metals [34,35] but limited proteolysis and atomic force 
microscopy experiments suggest that the core of large ag-
gregates formed by SOD1 is composed of residues 1-63 [36]. 
Molecular dynamic simulations, mass spectrometry and 
hydrogen/deuterium (H/D) exchange studies suggest local 
unfolding of the β-barrel and exceptional flexibility in the β 
strands 3 and 4 corresponding to residues 29-36 and 41-48 
[37–39]. These strands compose the β barrel and thus their 
rearrangement likely induces changes in the structure to 
enable secondary interactions that are important for aggre-
gation. In vivo models and cell culture studies also suggest 
that the N-terminal region of SOD1 plays an important role 
in toxicity, in particular residues such as Trp32 that may be 
important sites for post translational modifications [8,40,41]. 
Another study with shorter segments identified 4 different 
segments that are important for aggregation [42]. Mutations 
in two of these segments – 101-107 and 147-153 changed 
the aggregation propensity suggesting that these segments 
play an important role in the initiation of aggregation. The 
segment 147-153 lies at the dimer interface and this peptide 
segment can seed fibril formation of the full-length protein 
in vitro [42], suggesting that it plays an important role in 
aggregation.
SOD1 monomer also has 4 cysteine residues (Cys 6, 
Cys 57, Cys 111, and Cys 146) with Cys 57 and Cys 146 en-
gaged in a disulfide bond. The role of these Cys residues in 
SOD1 aggregation has been explored (reviewed in [23,43]. 
SOD1 mutations increase the aggregation propensity of 
disulfide-reduced apo-SOD1 [44,45] and aberrant disul-
fide-linked oligomers are detected in spinal cord homoge-
nates of transgenic mice [46]. However, mutating the cyste-
ine residues does not change the aggregation propensity of 
the protein [47]. Also, cysteine residues are not conserved 
across different species. Taken together, these reports sug-
gest that disulfide reduction is an important albeit non-crit-
ical step in the toxic aggregation pathway.
Overall, these biochemical and structural studies sug-
gest that SOD1 mediated toxicity is likely caused by a 
combination of different events such as aberrant disulfide 
reduction, the presence of a disease-associated mutation 
and reduced metal binding (Fig. 2). One or more of these 
events results in a shift in the equilibrium toward patho-
genic aggregation.
TOXIC SOD1 SPECIES – LARGE AGGREGATES 
OR SOLUBLE OLIGOMERS
The molecular stoichiometry of the toxic species in neu-
rodegenerative diseases has been intensely debated. While 
large aggregates are considered to be the pathological hall-
mark of Alzheimer’s or Parkinson’s disease and ALS, evi-
dence for small oligomers as the toxic entities has also been 
presented.
In case of SOD1, evidence for both large aggregates 
and small oligomers as the toxic species has been given. 
Large inclusions are a defining histological feature of pa-
tients and detergent insoluble aggregates are formed in 
animal models as well. However, the cause and effect re-
lationship between insoluble aggregates and motor neu-
ron death is unclear. Several studies of SOD1 suggest that 
small oligomers may also be toxic. In these experiments, 
disulfide reduced forms of mutant SOD1 were detected 
that may be the precursor species for the large aggregates 
[25,26,28,29]. The minimum toxic species has been pro-
posed to be trimeric with a non-native quaternary assem-
bly [48]. Similar trimeric assemblies have been proposed 
for other aggregating proteins such as tau [49], amyloid-β 
[50] and α-synuclein [51]. The structural details of these 
toxic oligomers have been elusive till now and it is also 
not known if the native SOD1 structure is intact or not.
PRION-LIKE BEHAVIOR OF SOD1
It is increasingly appreciated for neurodegenerative 
diseases that protein aggregates can transfer from cell to 
cell much like the aggregated forms of the PrP prion pro-
tein. Protein aggregates of α-synuclein [52–54], tau [55], 
β-amyloid [56,57] have been shown to act as templates for 
seeding native protein into aggregates as do prion proteins, 
a behavior termed ‘Prion-like’. However, the behavior of 
these proteins differs from the canonical prion proteins, as 
Table 1. Comparison of several SOD1 mutations
Location of mutation Mutations Aggregation propensity vs. wt Melting temperature vs. wt
β barrel G37R Similar Similar
Electrostatic loop N139K High Similar
Metal binding loop H46R,D134N, H80R, D124V High Low
Dimer Interface A4V, I113T High Low
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there is no evidence of transmission of disease between in-
dividuals by transfer of aggregates.
Several lines of evidence for transmission of SOD1 aggre-
gates have been found. SOD1 is abundant in the cytoplasm 
but has been reported also to be secreted extracellularly in 
vitro [58–60]. Additionally, co-culturing of non-neuronal 
cells such as astrocytes expressing mSOD1 induces toxicity 
in motor neurons expressing unmutated wtSOD1 [61,62]. 
However, it is not clear if the toxic effect on motor neurons 
is due to mSOD1 transmission or through a signaling cas-
cade. Overexpression of human wtSOD1 in mice express-
ing the familial mutant G85R accelerates the disease onset 
suggesting recruitment of wtSOD1 in aggregation [63]. It 
has also been shown that spinal cord homogenates from 
mSOD1 transgenic mice can seed aggregation of the protein 
in vitro [64]. Finally, injection of spinal cord homogenates in 
mice induces pathology that spreads to distant regions of 
the spinal cord [65–68]. Although mutant SOD1 forms in-
tracellular inclusions it is possible that a soluble, transferred 
form is sufficient for spread of pathology. Taken together, 
these studies suggest that SOD1 aggregation may initiate 
spontaneously in a section of motor neurons and could then 
be sequentially transferred from cell to cell. This hypothesis 
is also supported by the clinical disease progression, which 
starts with loss of a subset of motor neurons and then pro-
gresses through connected anatomical regions.
COMPARISON OF SOD1 WITH OTHER 
ALS-LINKED PROTEINS
Gene sequencing has associated nearly 30 different genes 
with ALS. A majority of these including TARDP, FUS, 
OPTN, VCP and hnRNP are RNA binding proteins that 
are also capable of forming aggregates in response to stress 
[69–71]. In these cases, the pathology appears to derive from 
both a loss of native function and gain of toxic function as 
disease causing mutations often render the protein func-
tionally inactive [72–74]. Indeed the mechanism of toxicity 
of RNA binding proteins seems to differ from that of SOD1. 
For RNA binding proteins defects in nuclear pore assembly 
and defective RNA processing [73,75,76] have been found 
whereas for SOD1, mitochondrial defects [77–80], golgi 
fragmentation [59], defects in proteasome machinery and 
axonal transport [77,81] have been found. These differenc-
es highlight an important realization that even though all 
forms of ALS are associated with protein aggregation, the 
mechanisms that cause toxicity are likely to differ from case-
to-case, depending on the proteins that are mutated.
Another aspect that differentiates SOD1 from other 
ALS-associated proteins such as TDP43, FUS and VCP 
is the exclusivity of mutant SOD1 to ALS. For example, 
aggregates of TDP43 are also found in Alzheimer’s and 
frontotemporal dementia (FTD) cases [82,83] , FUS is also 
associated with FTD [84] and VCP mutants are found in 
inclusion body myopathy with early-onset Paget disease 
and frontotemporal dementia (IBMPFD) [85]. In contrast, 
SOD1 mutants are associated only with ALS and there is 
no evidence of SOD1 aggregation in any other neurode-
generative disease. As all forms of ALS cases are clinically 
similar, researchers have studied the mechanism of disease 
onset in models of familial cases in hopes that the informa-
tion could be used to design drugs that would be effective 
against all forms of the disease. However, as more genes 
are implicated in ALS, it appears that even though protein 
aggregation is a central theme, the downstream effects of 
these aggregates may differ. Thus, it may be necessary to 
understand the toxic properties and disease pathway of 
each ALS-associated protein.
THERAPEUTIC DEVELOPMENT 
FOR SOD1-RELATED ALS
Various strategies have been explored to protect against 
SOD1 aggregation and to prevent neuronal loss. Among 
these siRNA-based gene silencing that reduces mutant 
SOD1 protein production was found to be well tolerated in 
phase 1 clinical trials [86,87]. A similar approach was also 
shown to be effective in a C9orf72 mouse model [88] and 
thus may be applicable to all forms of ALS.
In animal models, immunization approaches using an-
tibodies that bind to a disease-specific conformation have 
been shown to be marginally effective [89]. The anti-SOD1 
antibodies tested increased the life span of transgenic 
mice by 6–9 days and thus provide proof of concept for 
immunization therapy. Full-length SOD1 and its shorter 
segments such as peptide 143-151 that lies at the dimer 
interface have also been used to elicit immune response 
in animal models [90,91]. This vaccination approach was 
successful in delaying disease onset by 28 days and in-
creased the overall lifespan of transgenic mice by 40 days.
With the advent of stem cell differentiation and induced 
pluripotent stem cells (iPSCs), patient derived motor neu-
rons are being used to discover small molecule therapeutics. 
Patient-derived motor neurons show reduced survival and 
recapitulate the defects seen in transgenic mouse models 
such as reduced axon transport and mitochondrial defects 
[77,92]. Stem cell-derived motor neurons offer a fast meth-
od for high throughput screening of potential therapeutics. 
Indeed the first few studies have yielded several small mol-
ecules that inhibit aggregation in vitro and alleviate the toxic 
effects in cell culture [93,94].
Intriguingly, all ALS-linked mutant proteins are ex-
pressed ubiquitously in all tissues yet they aggregate 
only in the spinal cord. In this regard, some studies have 
focused on identifying a protective factor that may be 
present in non-neuronal tissues. In one study, a chaper-
one MIF2 (macrophage inhibitory factor) that expresses in 
non-neuronal tissues was discovered that inhibits SOD1 
aggregation [95]. In a parallel approach, over expression 
of chaperones such as HSJ1 [96] and Hsp110 [97] specif-
ically in spinal motor neurons conferred protection. In a 
related study, a small molecule inhibitor, Sephin1 was 
developed that activates the proteasome system and in-
creases chaperone production [98]. Sephin1 reduced the 
motor deficits and insoluble aggregate formation in trans-
genic mice expressing G93A mSOD1. Although these re-
sults are preliminary, they suggest that over-expression 
of individual chaperones or stimulating chaperone pro-
duction have therapeutic potential.
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A promising approach to therapy for amyloid diseases 
is stabilizing the native structure of proteins such that the 
equilibrium shifts away from aggregation. This approach 
has most successfully been applied for transthyretin [99] 
and light chain amyloidosis [100] but it remains unexplored 
for SOD1 till now. A few studies have shown that stabilizing 
the native structure of SOD1 by chemical crosslinking or by 
small molecules delays aggregation [101–103]. Intriguing-
ly, when these compounds were co-crystallized with SOD1 
they were found to bind not at the dimer interface but to the 
β-barrel, in particular β-strands 2, 3 and 6 suggesting that 
these strands play a role in aggregation.
CONCLUSIONS
Since its discovery as an ALS-linked protein, SOD1 has 
been extensively studied in vitro, in cell culture, and in ani-
mal models. Overall, various hypotheses such as increased 
aggregation propensity, dimer destabilization and oligom-
erization have been proposed for mSOD1 toxicity that may 
not be mutually exclusive. It is conceivable that under dif-
ferent conditions such as presence of a mutation, oxidative 
stress, and aberrant metal binding different mechanisms for 
toxicity are initiated.
Critical questions that remain unanswered include: the 
structure of the toxic species, the role of SOD1 in sporad-
ic ALS, the mechanism of prion-like, intercellular spread 
of aggregates, and whether SOD1 and other ALS-linked 
proteins share a common pathogenic pathway. Answering 
these critical questions will ultimately help to defeat this 
devastating disease.
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STRESZCZENIE
Stwardnienie zanikowe boczne (ALS) to śmiertelna choroba neurodegeneracyjna charakteryzująca się postępującą degeneracją neuronów 
motorycznych rdzenia kręgowego. Z ALS powiązano obecność mutacji w wielu białkach, jednak to dysmutazę ponadtlenkową 1 (SOD1) jako 
pierwszą powiązano z rozwojem ALS; jest ona odpowiedzialna za około 20% rodzinnych wystąpień tej choroby. U zwierząt doświadczalnych 
i w próbkach pobranych od pacjentów zmutowana forma SOD1 została wykryta w złogach cytoplazmatycznych, co świadczy o toksyczności 
jej agregatów. W niniejszym artykule przedstawiono różne hipotezy oparte na danych biochemicznych i strukturalnych wyjaśniające rozwój 
ALS związany ze zmutowaną formą SOD1. Choć molekularne mechanizmy leżące u podstaw toksyczności SOD1 są w znacznym stopniu 
nieznane, przedstawione modele mogą wskazywać na nowe możliwości opracowywania skutecznej terapii.
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Chapter 2: Atomic structure of a toxic, oligomeric segment of SOD1 linked to amyotrophic 
lateral sclerosis (ALS) 
 
Abstract: Fibrils and oligomers are the aggregated protein agents of neuronal dysfunction in 
Alzheimer’s, Parkinson’s and Lou Gehrig’s (ALS) diseases. Whereas we now know much about 
fibril architecture, atomic structures of disease-related oligomers have eluded determination. 
Here we determine the corkscrew-like structure of a cytotoxic segment of SOD1 in its oligomeric 
state. Mutations that prevent formation of this structure eliminate cytotoxicity of SOD1 on 
primary motor neurons and in a Danio Rerio (zebrafish) model of ALS. Moreover, a novel 
antibody detects corkscrew-like epitopes in neural tissue samples collected from ALS patients. 
Our findings add to evidence that the toxic oligomeric entities in protein aggregation diseases 
contain antiparallel, out-of-register β-sheet structures, and identify a target for structure-based 
therapeutics for ALS. 
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Abstract: Fibrils and oligomers are the aggregated protein agents of neuronal 
dysfunction in Alzheimer’s, Parkinson’s and Lou Gehrig’s (ALS) diseases. Whereas we 
now know much about fibril architecture, atomic structures of disease-related oligomers 
have eluded determination. Here we determine the corkscrew-like structure of a cytotoxic 
segment of SOD1 in its oligomeric state. Mutations that prevent formation of this 
structure eliminate cytotoxicity of SOD1 on primary motor neurons and in a Danio Rerio 
(zebrafish) model of ALS. Moreover, a novel antibody detects corkscrew-like epitopes in 
neural tissue samples collected from ALS patients. Our findings add to evidence that the 
toxic oligomeric entities in protein aggregation diseases contain antiparallel, out-of-
register β-sheet structures, and identify a target for structure-based therapeutics for ALS. 
 
Main Text:  
Since Alzheimer’s pioneering report in 1906, fibrillar protein deposits have been linked 
to neurodegenerative diseases. More recently, this link has been challenged by findings 
that transient, soluble oligomers formed by these proteins are cytotoxic (1–3). Whereas 
atomic- resolution structures of the spines of amyloid fibrils have shown tightly packed 
β-sheets with inter-digitated side chains (4–9), atomic-level details of toxic oligomers 
remain elusive. Various reports suggest that toxic intermediates formed by amyloid 
forming proteins consist of anti-parallel β sheet-rich structures (10–15). These reports 
utilized chemical cross-linking, analytical size exclusion, electron microscopy and FTIR, 
but no crystal structure of a toxic amyloid oligomer has been reported. 
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ALS is a debilitating disease, destroying spinal motor neurons and often leading to death 
within a few years of symptom onset. More than 160 different mutations in SOD1, a 
metal-binding, dimeric protein of 153 residues, are found in familial cases of ALS (16). 
SOD1 aggregation has also been implicated in sporadic ALS pathogenesis (17, 18). Most 
of these SOD1 mutants show little change in enzymatic function suggesting that toxicity 
derives not from a loss of native function, but from a gain of toxic function (19, 20). 
Transgenic mouse models of the familial mutants show motor neuron degeneration and 
stain positive for SOD1-containing inclusions, suggesting that protein aggregation is a 
mode of toxicity (21–23). Enrichment of oligomers has also been observed in cell culture 
(24, 25) and in transgenic mice (26, 27). However, a causal relationship between the 
appearance of aggregates and neuronal death has not been conclusively supported, and no 
atomic structure has been described for toxic oligomer of SOD1 or any other 
neurodegenerative-disease-related protein. Here we propose a structure for toxic 
oligomers formed by SOD1. 
  
Crystal structure of the segment (residues 28-38) reveals an anti-parallel β sheet 
oligomer: 
 
Based on mutational studies of others (28–31) and our own (see below), we focused on 
residues (28-38) of SOD1 as having the potential to form a toxic amyloid oligomer (Fig. 
S1, S2, S3, Supp. Text). To determine the structure of this segment we needed to increase 
its solubility.  We achieved this by engineering a single residue replacement:  proline to 
lysine at the N-terminal position 28. Rod-like crystals, 5 µm in one dimension appeared 
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overnight and upon further optimization yielded diffraction to 2.0 Å resolution. We 
phased the diffraction data by single isomorphous replacement with anomalous scattering 
(SIRAS) from crystals soaked in potassium iodide (Table S1). The crystal structure 
shows a twisted β-sheet built of antiparallel, out-of-register β-strands.  Describing its 
shape, we term it the corkscrew (Fig. 1A). The exterior of the corkscrew is largely polar, 
while the hydrophobic interior is filled with aliphatic side chains of valine, leucine and 
isoleucine (Fig. 1A, right, S4). The N-terminal residues 29-35 form the β strand and the 
C-terminal residues, lysine, glycine and leucine form a beta-hairpin, which contributes 
weakly to the corkscrew assembly.  
Corkscrew shows structural similarities to cylindrin, an oligomer of a non-pathogenic 
amyloid-forming protein (32). Similar to cylindrin, corkscrew is also composed of 
antiparallel β-strands that are out-of-register and form alternating weak and strong 
interfaces with neighboring β-strands (Fig. S5). The strong interface is composed of 9 
inter-chain hydrogen bonds whereas the weak interface is composed of 7 hydrogen bonds 
- 1 intra-main chain and 6 inter-main chain hydrogen bonds. The buried surface area of 
one strand relative to the assembly (984 Å2 vs 943 Å2) and shape complementarity (0.79 
vs 0.74) of the two structures are also comparable (Table S2). However, an important 
difference between the two architectures is that cylindrin is a closed barrel of 6 strands 
whereas corkscrew is an open barrel extending indefinitely as a twisted sheet, forming 
one complete turn every 16 strands. Oligomers formed by several other proteins such as 
α-synuclein, amyloid-β and HET-s have also been reported to be β-sheet rich (11–13, 33). 
However, there is also evidence for polymorphism for the different oligomers that differ 
in size, architecture and toxic properties (34–36). Indeed, oligomeric structure of a single 
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protein can also differ depending on preparation conditions and consequently differ in 
biochemical properties (37). Taking the corkscrew structure described here, along with 
reports of amyloid oligomers described by others suggests that antiparallel, out-of-
register β-strand architecture may be a common motif of amyloid oligomers (13, 34, 38). 
From the crystal structure we observed that the N-terminal Lys28 replacing proline does 
not form any critical contacts and contributes only weakly to the crystal lattice contacts 
(Fig. S6A). Lys28 in the corkscrew structure is engaged in two hydrogen bonds; one with 
the C-terminal carboxylate and another with the carbonyl oxygen of Ser34. The native 
sequence maintains the same capacity for hydrogen bonds with these two hydrogen bond 
acceptors (Fig. S6B). Thus, the proline to lysine replacement has no effect on the 
corkscrew structure.   
 
The segment 28-38 includes the longest stretch conserved in all known ALS cases and 
has been previously hypothesized to be important for aggregation (28). However, it also 
includes a number of familial mutations including the intensely studied, familial mutant, 
G37R and the rare mutants, V29A and V31A. From the crystal structure, we deduce that 
these mutations are compatible with the corkscrew structure. 
 
We modeled the rest of full-length SOD1 around the corkscrew keeping the native 
tertiary structure of SOD1 intact. We used the apo-SOD1 monomeric structure as our 
starting model. Biochemical studies have noted that metal-depleted monomer is prevalent 
in patient tissues (39–41) as well as mice models (27, 42) and is an intermediate in the 
conversion of native holo-SOD1 to pathological aggregates. We find that the remaining 
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residues can be accommodated with minimal change in secondary structure (Fig. 1B). 
Strands 2 and 3 detach from the monomer to allow corkscrew-like assemblies to form. 
While this model is currently speculative, it agrees with H/D exchange, molecular 
dynamics (MD) and mass spectrometry studies by others showing that most familial 
SOD1 mutants have minimal change in their secondary structure and contain a partially 
unfolded β-barrel at physiological temperature with local unfolding in β strand 3 
corresponding to segment 29-36 (29, 43).  
We hypothesize that corkscrew-like oligomers of SOD1 resemble subsets of the 
indefinitely long twisted sheets modeled here on the framework of the corkscrew crystal 
structure. A single preferred oligomer size is not indicated by our structural model. Our 
observation that the corkscrew is composed of a single β-sheet, rather than several packed 
sheets as in amyloid fibrils, suggests that its fragmentation should be relatively facile, and 
would limit the size of SOD1 oligomers. Because our corkscrew-based model of SOD1 
oligomers does not require the complete unfolding of SOD1, globular segments of SOD1 
around the periphery of the corkscrew segment could block indefinite growth of the 
oligomer by shielding the sheet edges. Such a mechanism of limiting oligomer growth 
could not be observed in our crystal structure since the globular regions were excluded 
from crystallization. 
Examining the corkscrew structure, we noticed that the glycine at position 6 (position 33 
in full-length SOD1) is essential for corkscrew formation (Fig. 1C). Residues with larger 
side chains at position 33, such as tryptophan (Fig. 1D) cause steric clashes destabilizing 
the corkscrew structure. Consistent with this observation, in our all-atom MD simulations 
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the G33W mutant structure was less stable than the wild-type structure with both native 
proline and modified lysine residues at the N terminus (Fig. 1E, S7). 
 
We also performed ion mobility mass spectrometry experiments to confirm that the 
segment forms oligomers in solution similar in cross-section to the crystal structure of the 
corkscrew (Supp text, Fig. S8, Table S3). The SOD1 segment was also observed to 
preferentially assemble into a corkscrew-like structure in our MD simulations (Fig. 1F, 
S9).  
 
Segment (28-38) is necessary and sufficient for toxicity: 
We next asked if the segment is cytotoxic and if the corkscrew structure underlies its 
toxicity. To examine cytotoxicity, we used embryonic stem-cell-derived motor neurons 
labeled with green fluorescent protein (44). The corkscrew-forming segment was 
aggregated and applied to motor neurons and cellular viability was measured upon 
overnight treatment. We found that viability was reduced by 60% compared to buffer-
treated cells at physiologically relevant concentrations of 8-100 µM in a dose-dependent 
manner (Fig. 2A) (45). In contrast, the segment harboring a single G33W substitution that 
disrupts corkscrew formation did not induce any toxicity in cells at any concentration 
tested (Fig. 2B). We also tested replacement of Gly33 with a less bulky residue, valine, 
and found that it was also sufficient to alleviate toxicity of the segment (Fig. 2B, S10). 
The segment harboring the native proline residue is also cytotoxic and mutation at Gly33 
to tryptophan or valine renders the peptide segment non-toxic (Fig. S11).  
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To further validate our hypothesis that the corkscrew structure forms the basis of SOD1-
mediated toxicity in ALS, we studied two familial mutants of full-length SOD1 – A4V 
and G93A (46). We introduced the corkscrew-disrupting substitutions at Gly33 on the 
background of both of these familial mutations. Proteins were recombinantly expressed 
and aggregated by demetallation and agitation at 37°C for 12 hours, which produced a 
mixture of fibrils and oligomers. Motor neurons were treated with aggregated proteins 
overnight and cellular viability measured thereafter. A4V and G93A mutants were toxic 
to the cells at 8 µM, which appeared drastically degenerated compared to buffer-treated 
cells (Fig. 2C). By contrast, A4V/G33V, A4V/G33W, G93A/G33V and G93A/G33W 
proteins were non-toxic at the same concentration, and cellular morphologies were 
indistinguishable from those of the buffer-treated cells. We also quantified cellular 
viability, confirming that A4V and G93A were toxic to cells (Fig. 2D) and that the 
introduction of the corkscrew-disrupting substitutions at Gly33 alleviates their toxic 
effects. Together, these data suggest that the SOD1 segment (28-38) is both necessary 
and sufficient for motor neuron toxicity. 
 
Toxicity of full-length SOD1 derives from soluble oligomers: 
 
To determine whether the toxicity of full length SOD1 derives from soluble oligomers or 
insoluble fibrils, we tested the cytotoxic effects of the non-fibril-forming mutant (I104P) 
(26). While I104P protein did not form any mature fibrils (Fig. 2E), it was nevertheless 
toxic to motor neurons. The addition of the corkscrew-disrupting substitution G33W 
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alleviated this cytotoxicity (Fig. 2F, 2G). These results suggest that fibril formation is not 
essential for cytotoxicity. 
 
To further investigate the origin of toxicity, we performed a series of experiments 
monitoring the aggregation kinetics of the various SOD1 mutants. In these experiments, 
we aggregated the proteins for different amounts of time and measured their cytotoxicity. 
We found that both familial mutants (A4V and G93A) were toxic to cultured neurons 
when aggregated for 12-16 hours and extended aggregation for 72 hours rendered the 
protein non-toxic (Fig. 2H, 2I). A4V/G33W and G93A/G33W were non-toxic 
irrespective of the duration of aggregation. Negative stain electron microscopy showed 
abundant fibrils in the samples aggregated for 72 hours and immunoblotting with the 
conformational oligomer specific antibody (A11) suggested samples aggregated for 72 
hours contained no oligomers (Fig. S12). These results suggest that toxicity of aggregated 
SOD1 mutants derives from oligomers. 
 
Several reports suggest that wt-SOD1 also aggregates in sporadic ALS (47–49). 
However, there is a lack of cellular and animal models that recapitulate wt-SOD1 (WT) 
toxicity and it is also not clear if WT and mutants have similar mechanisms of 
aggregation and toxicity. Therefore, we asked if WT differs in aggregation and toxicity 
from the familial mutants in our assays. To monitor the kinetics of fibril formation in 
these experiments, we used Thioflavin T, a dye that fluoresces upon binding to fibrils. 
The fibril-forming behavior of WT, G93A, and G33W constructs were similar, displaying 
a lag time of 2-4 hours, presumably during small-oligomer formation, followed by a short 
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log phase and then a plateau indicative of mature-fibrils (Fig. S13). We then performed 
the motor-neuron-cytotoxicity assay with protein aggregates from several time points. 
We found that WT or G93A protein samples that were allowed to aggregate for up to 12 
hours were toxic to the motor neurons, whereas the same protein preparations that were 
aggregated for 16 hours or more exhibited no toxicity (Fig. S13A, S13B). Electron 
microscopy showed no mature fibrils in samples aggregated up to 12 hours (Fig. S13). In 
contrast, samples shaken for 16 hours or longer exhibited large fibril loads and were non-
toxic to motor neurons. G33W, which cannot form the corkscrew, was non-toxic 
regardless of the extent of fibril formation (Fig. S13C). Thus, WT and mutant SOD1 
share similar mechanisms of cytotoxicity that resides in residues (28-38) although other 
segments may enhance aggregation by initiating unfolding.  
 
Taken together, our data suggest that toxicity of aggregated SOD1 derives specifically 
from oligomers that are off-pathway from fibrillation (Fig. S14). Our findings for SOD1 
align with the hypotheses proposed by others for amyloid beta and huntingtin that large 
insoluble aggregates are relatively inert deposits (50–53). 
 
Corkscrew disruption alleviates defects in a Danio rerio (zebrafish) ALS model: 
 
To examine the effect of the corkscrew-disrupting mutation in vivo, we turned to a 
zebrafish model of ALS in which familial SOD1 mutants cause axonopathies (54–57). 
We expressed A4V SOD1 with and without the corkscrew-disrupting substitution at 
Gly33 in a zebrafish TDL6 line in which the primary motor neurons are labeled with GFP 
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and the mitochondria are labeled with dsRed (58). We analyzed motor axons at 2 days 
post fertilization (dpf). A4V caused 8% reduction in axon length (Fig. 3A, 3B) as has 
been previously shown (56), but A4V/G33V-injected fish had normal axon lengths (Fig. 
3A, 3B). Additionally, we observed 30% of A4V but not the WT or double mutants 
injected embryos were severely deformed and could not be imaged suggesting that an 
acute phenotype is lethal (Fig. S15). We observed a similar phenotype upon expression of 
G93A – G93A-expressing zebrafish have 5% reduction in axon lengths while 
G93A/G33V expressing zebrafish were significantly better (Fig. 3C, 3D).  
 
Defects in mitochondrial assembly and trafficking along with vacuolation (59, 60) and 
abnormal clustering in neuronal processes (61–64) are established pathological 
phenotypes observed in transgenic mice, patient derived cells and other models. 
However, they have not been reported in any zebrafish model of ALS. Therefore we 
analyzed the mitochondrial morphology upon expression of SOD1 familial mutants. 
Expression of A4V mutant protein caused remarkable mitochondrial pathology 
characterized by abnormal clustering at the branch points indicative of defective 
mitochondria (Fig 3E) whereas A4V/G33V expressing fish had a mitochondrial network 
similar to WT fish. These defects were quantified by measuring the size and number of 
the mitochondria confirming that A4V had enlarged mitochondria (Fig 3F, S15) that were 
fewer in number (Fig 3G, S15). We also observed similar defects in the G93A-expressing 
zebrafish (Fig 3H, 3I, S15). Thus, disrupting the corkscrew segment alleviates ALS-
linked axonopathies and mitochondrial defects in this in vivo model.  
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A novel antibody against corkscrew antigen recognizes apo-SOD1 oligomers: 
 
We also found evidence that aggregated SOD1 in familial ALS patients exhibits a 
corkscrew-like epitope. From our model of full-length SOD1 oligomers, we observed that 
residues Val29, Val31, Gly33 and Ile35 are exposed at the ends of the corkscrew (Fig 
4A). These residues are buried in the native SOD1 structure. We utilized this difference 
of solvent accessibility to develop an antibody (CSAb) specific for the corkscrew 
conformation. CSAb recognizes an epitope present in the oligomers of the segment but 
not in the fibrils (Fig. 4B, S16).  CSAb does not recognize native dimeric SOD1 (Fig. 4C) 
or insoluble fibrils prepared by aggregation for 72 hours that are non-toxic (Fig. 4E). 
CSAb also fails to recognize denatured metal-bound SOD1 either purified recombinantly 
or from cell lysates although it recognizes denatured apo proteins (Fig. 4D). This 
selectivity on a denatured western blot suggests that there is some degree of 
conformational specificity associated with CSAb. CSAb also does not recognize the 
corkscrew disrupted G33W mutant proteins (Fig. S17). However, it recognizes toxic 
oligomers of apo-G93A prepared by aggregating for 12 hours (Fig. 4E, S16). Blue-native 
gel electrophoresis followed by western blotting showed that CSAb-positive oligomers 
are soluble and range from 30-100 kDa in mass, or about 2-6 monomers (Fig. 4F). 
Finally, we co-incubated 8 µM apo-G93A protein with 0.5 µM CSAb and found that it 
neutralized the toxicity of apo-G93A, supporting our conclusion that the segment (28-38) 
is a critical epitope for cytotoxicity (Fig. 4G). 
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We used CSAb to test for the presence of corkscrew oligomers in ALS and healthy 
human spinal cord specimens. CSAb positive staining was observed in the motor neurons 
of 4 out of 6 SOD1-linked fALS cases, 3 out of 6 sALS and 4 out of 5 non-SOD1 fALS 
but not in the healthy human subjects (Figure 4H, 4J, S18, Table S4). Interestingly, we 
also observed staining in non-neuronal cells, in particular, in 4 SOD1-linked fALS 
patients and in 3 non-SOD1 fALS subjects similar to previous reports (Fig. 4I, 4K) 
(22,56). Taken together, CSAb suggests that the SOD1 segment containing residues (28-
38) is involved in the development of ALS, possibly in the corkscrew conformation. 
 
In summary, we have identified an 11-residue segment in ALS-associated SOD1 that is 
necessary for its cytotoxicity. Our data support the hypothesis that SOD1 forms toxic 
oligomers composed of antiparallel, out-of-register β-sheet structures involving residues 
28-38. This cytotoxic segment may be a target for developing structure-based ALS 
therapeutics. 
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Figure Legends 
 
Fig. 1. Structure of the corkscrew, an oligomer-forming segment of SOD1  
(A) 2.0 Å resolution crystal structure of the SOD1 segment with sequence 
KVKVWGSIKGL shows antiparallel, out-of-register β-strands forming a continuous left-
handed helix. Sixteen strands form one complete turn of the helix, with 25 Å outer 
diameter and 71 Å pitch. The hydrophobic interior lined with valine, isoleucine, and 
leucine side chains excludes water molecules, as shown in side and top views.   
(B) Model of the SOD1 toxic oligomer built of 16 monomers on the spine of the 
corkscrew crystal structure. Strands 2 and 3 detach from the native SOD1 fold to form the 
corkscrew spine. The remaining protein decorates the exterior of corkscrew with much of 
the SOD1 structure intact. The model is shown in the same two orientations as (A). One 
monomer is colored in brown for clarity. Notice that the segment (28-38) is buried in the 
core but it is exposed at the edges.  
(C) Val29 and Val31 of alternate β-strands form a hydrophobic interaction and are 
accommodated by the lack of a Gly33 side chain on the intervening strand.  
(D) A PyMol-generated figure illustrates the steric clash caused by mutating Gly33 to 
tryptophan.  
(E) All-atom MD simulations of the corkscrew-forming segment suggest that 
introduction of the G33W substitution destabilizes the structure. Blue and red curves 
correspond to Cα root-mean-square deviations (RMSD) from the corkscrew crystal 
structure in MD simulations of 8 chains of the corkscrew segment (KVKVWGSIKGL) 
and G33W mutant segment (KVKVWWSIKGL), respectively. The structure of the 
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corkscrew segment remained stable throughout the length of the simulation, whereas the 
G33W mutant deviated from the corkscrew structure.  
(F) The SOD1(28-38) segment preferentially assembled into a corkscrew-like structure in 
MD simulation. MD simulations of weakly restrained monomers of SOD1 spontaneously 
assembled into a corkscrew-like structure. A snapshot of an assembled corkscrew-like 
structure from the MD simulations (green) is overlaid onto the crystal structure (blue). As 
a control, we found that monomers of the cylindrin-forming segment of αB crystallin 
spontaneously assembled into a cylindrin structure using the same simulation protocol 
(see SI text and Fig. S9 for additional simulation details). 
 
Fig. 2. Corkscrew-forming segment (28-38) is necessary and sufficient for 
cytotoxicity 
(A) Cell viability of motor neurons measured by MTT reduction assay shows that the 
corkscrew segment (KVKVWGSIKGL) is toxic to primary motor neurons in a dose-
dependent manner. Statistical significance was analyzed using two tailed T-tests with 
Welch’s correction. 
(B) Corkscrew-forming segment (28-38) harboring single point substitutions at Gly33 
(G33V and G33W) is non-toxic to motor neurons. All peptide segments were prepared 
identically and motor neurons were treated with different final concentrations. Statistical 
significance of G33 mutants was compared to the 28-38 segment by two-way ANOVA. 
(C) Hb9-GFP labeled motor neurons treated with 8 µM aggregated full-length familial 
mutants (A4V and G93A) lose neurites but the corresponding double mutants 
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(G93A/G33V, G93A/G33W, A4V/G33V and A4V/G33W) are non-toxic and neurons 
look healthy. (Scale bar = 20 µm) 
(D) Cell viability measured by MTT reduction assay confirming that the familial mutants 
A4V and G93A are toxic and substitution of Gly33 with Valine or Tryptophan renders 
the protein non-toxic. Statistical significance was analyzed by one-way ANOVA. 
(E) Electron micrographs of a non-fibril forming SOD1 mutant (I104P) and the 
corresponding double mutant (I104P/G33W) show some aggregates but no large fibrils.  
(F) Motor neurons treated with I104P lose neurites and have shrunken cell bodies (left) 
but I104P/G33W treated cells look healthy.  
(G) Cell viability measured by MTT reduction assay confirmed that I104P is toxic and 
I104P/G33W is non-toxic. Statistical significance was analyzed using a two-tailed T-test 
with Welch’s correction. 
(H,I) The toxic properties of SOD1 mutants depend on the duration of aggregation. A4V 
and G93A mutants aggregated for 12-16 hours are toxic to motor neurons while extended 
agitation for 72 hours renders the proteins non-toxic. The corkscrew-disrupted proteins 
(A4V/G33W and G93A/G33W) are non-toxic irrespective of the duration of aggregation. 
Statistical significance was analyzed by two-tailed T-tests with Welch’s correction. 
Results shown as Mean+SD (n=3). Symbols represent individual values of triplicates and 
bars represent average values. (*p< 0.05, (**p<0.01,***p< 0.001,****p<.0001). 
 
 Fig. 3. Corkscrew-disrupting substitution of G33V alleviates axonopathies in a 
Danio Rerio (zebrafish) ALS model  
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(A) Micrographs of zebrafish embryos at 2 dpf show reduction in axon length of A4V–
expressing embryos, whereas corkscrew-disrupted A4V/G33V–expressing embryos have 
normal axon lengths. The first axon is highlighted in pink for clarity and axons measured 
for quantification are marked by an asterisk. Scale bar 100 µm.   
(B) Quantification of axon lengths show that A4V–expressing embryos have shorter 
axons than WT-expressing embryos. The corkscrew-disrupting substitution G33V 
alleviates the defect. Results shown as Mean+SEM relative to WT for at least 72 
embryos. Statistical significance was analyzed using one-way ANOVA. 
(C) Micrographs of zebrafish embryos at 2 dpf show reduction in axon lengths of G93A–
expressing embryos, whereas corkscrew-disrupted G93A/G33V–expressing embryos 
have normal axon lengths. The first axon is highlighted in pink for clarity, and axons 
measured for quantification are marked by an asterisk. Scale bar 100 µm.   
(D) Quantifications of axon lengths show that G93A–expressing embryos have shorter 
axons than WT-expressing embryos. The corkscrew-disrupting substitution, G33V 
alleviates the defect. Results shown as Mean+SEM relative to WT for axons 12-16 of at 
least 73 embryos. Statistical significance was analyzed using one-way ANOVA. 
(E) Micrographs show A4V-expressing zebrafish have impaired mitochondria which are 
clustered at the branch points (encircled) as compared to WT. Mitochondrial network of 
A4V/G33V-expressing embryos is similar to WT.   
(F,G) Quantitative analysis of the mitochondrial network shows A4V-expressing fish 
have larger mitochondrial size (30.17 a.u.) and fewer mitochondria (32) in the axons 
indicative of defective fission whereas A4V/G33V (10.57 a.u. size and 54 mitochondria) 
expressing embryos have healthy mitochondria similar to WT (14.08 a.u. size and 58 
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mitochondria). Symbols represent individual measurements made in five motor neurons 
in 3 fish for each group. Statistical significance was analyzed by one-way ANOVA.  
(H,I) Quantitative analysis of the mitochondria network show G93A-expressing fish have 
larger, diffused mitochondria (14.68 a.u. size and 39 mitochondria). Mitochondrial 
network of G93A/G33V (11.68 a.u. size and 59 mitochondria) expressing embryos is 
similar to WT (10.78 a.u. size and 78 mitochondria). Statistical significance was analyzed 
by one-way ANOVA.  
Results shown as Mean+SEM. Symbols represent individual values and bars represent 
average values. (*p< 0.05, **p<0.01,***p< 0.001,****p<.0001). 
  
 
Fig. 4. Corkscrew-based monoclonal antibody (CSAb) is reactive for SOD1 in fALS 
tissue sections.  
(A) Solvent accessibility of the segment (28-38) (blue) in full-length SOD1 oligomers is 
evident in this space-filing model. In particular, residues Val29, Val31, Gly33 and Ile35 
that are buried in the native SOD1 structure are exposed at the ends of the corkscrew 
model. Therefore, an antibody specific for the corkscrew conformation would recognize 
only oligomers and not native SOD1.    
(B) CSAb detects oligomers (O) of the (28-38) segment but not fibrils. SODAb (a 
monoclonal antibody that recognizes the linear epitope corresponding to residues 24-36) 
was used to compare loading and electron microscopy was used to confirm the presence 
of fibrils (Fig. S16).  
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(C) Dot blot assay showing that CSAb does not detect native, dimeric metal-bound 
proteins.  
(D) SDS-PAGE western blot shows CSAb does not recognize denatured recombinant 
protein or SOD1 extracted from cell lysates although it recognizes metal depleted apo-
proteins.  
(E) Dot blot assay showing CSAb does not recognize insoluble fibrils (F) (aggregated for 
72 hours) but detects oligomers (O) (aggregated for 12 hours) of full-length apo-G93A 
(Refer Fig. S13 for toxicity). A11 antibody was used to confirm the presence of 
oligomers. SOD100 (a polyclonal antibody that recognizes all forms of SOD1) was used 
to compare loading and electron microscopy was used to confirm the presence of fibrils 
(Fig. S16).  
(F) Blue-native PAGE western blot of the apo-G93A shows soluble oligomers 
recognized by CSAb range from approximately 30 kDa to 100 kDa, in size, and the 
fibrillar preparations have no detectable oligomers. The molecular weight of the SOD1 
monomer is 17 kDa, so the oligomers range from about 2 to 6 monomers. 
(G) CSAb neutralizes the toxicity of SOD1 oligomers. 8 µM apo-G93A protein 
aggregated for 12 hours was co-incubated for 2 hours with 0.5 µM CSAb or equal 
amounts of an unrelated IgG1 or buffer. The mixture was then applied to motor neurons 
and toxicity was measured after 24 hours by cellular morphology as well as by MTT 
reduction assay. Co-incubation with CSAb neutralizes the toxicity but equal volumes of 
buffer or unrelated IgG1 are ineffective suggesting that the epitope (28-38) is critical for 
cytotoxicity. Symbols represent individual measurements and bars represent average 
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values. Statistical significance was analyzed using one-way ANOVA (***p< 0.001, ns 
not significant).  
(H, I) CSAb reactivity was tested in spinal cord tissues from 6 SOD1-linked fALS, 5 
non-SOD1 linked fALS, 6 sALS and 10 control subjects. Cytoplasmic reactivity (marked 
by arrows) was observed in the motor neurons of majority of ALS subjects with strongest 
reactivity in SOD1-linked fALS subjects. Nuclear staining (marked by arrowheads) was 
observed in non-neuronal cells of fALS subjects but not in control or sALS subjects.  
(J,K) Ratio of positive neuronal and non-neuronal cells in control, SOD1-linked fALS, 
non-SOD1 fALS and sALS (see Table. S4 for clinical information). Five fields of view in 
one section chosen randomly from 5 stained sections were counted per subject. Symbols 
represent individual measurements and bars represent average values. Statistical 
significance was analyzed using one-way ANOVA (**p<0.01,****p<0.0001, ns not 
significant). 
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Materials and Methods 
 
SOD1(28-38) structure determination  
Crystals of SOD1(28-38) with a P28K residue change were grown in hanging drop VDX 
plates (Hampton Research, Aliso, Viejo, CA). Lyophilized peptide at 98% purity 
(Genscript Inc.) was dissolved to 50mg/ml in 50mM Tris-base buffer. The reservoir 
solution contained 0.2M Na Citrate pH 5, 13% PEG 6000. Thick rod-like crystals 
appeared overnight and were allowed to grow for 2-3 days at ambient temperature in 2µL 
drops with a ratio of 2:1 peptide:reservoir. For heavy metal soaking, a 0.5M KI stock 
solution was made in the reservoir solution. The crystals were soaked for 30 seconds in a 
solution composed of a 2:1 ratio of the 0.5M KI stock solution to reservoir solution and 
10% glycerol stock for cryoprotection. The crystals were subsequently flash frozen in 
liquid nitrogen. Single crystals were mounted with CrystalCap HT Cryoloops (Hampton 
Research, Aliso Viejo, CA). All data were collected at the Advanced Photon Source 
(Chicago, IL) on beamline 24-ID-E, which has a 5 µm microfocus beam suitable for the 
crystals. All data were processed using DENZO and SCALEPACK or XDS (1). Phases 
were obtained by heavy atom soaking and the structure was solved by SIRAS, followed 
by model building using COOT (2). All model refinement was done using REFMAC (3) 
and BUSTER (4). Figures were generated using PyMol (5). Unless stated otherwise, 
SOD1(28-38) in the text refers to KVKVWGSIKGL. 
 
Molecular Dynamics simulations 
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We performed all-atom MD simulations of SOD1 and αB crystallin on Anton (6, 7), a 
special-purpose computer designed to accelerate standard molecular dynamics 
simulations by orders of magnitude. Protein, water, and ions were represented explicitly, 
using the AMBER 99SB*-ILDN (8–10) force field and the TIP3P water model (11).  
Simulations of the SOD1 corkscrew were initiated from the crystal structure comprised of 
an eight-stranded corkscrew with either a wild-type (KVKVWGSIKGL and 
PVKVWGSIKGL) or G33W mutant (KVKVWWSIKGL and PVKVWWSIKGL) 
monomer sequence.  Initial structures were placed in a cubic box 76 Å on each side and 
solvated with approximately 13,000 water molecules and 150 mM NaCl. The systems 
were minimized and then equilibrated in the NPT ensemble at 1 bar and 300 K for 50 ns 
with 5 kcal mol−1 Å−2 harmonic position restraints applied to all non-hydrogen atoms of 
the protein; these restraints were tapered off linearly over 50 ns.  Production runs were 
initiated from the final snapshot of the equilibration run and performed in the NVT 
ensemble using a 2.5-fs time step.  Non-bonded interactions were truncated at 12 Å. The 
wild-type (KVKVWGSIKGL and PVKVWGSIKGL) and G33W mutant 
(KVKVWWSIKGL and PVKVWWSIKGL) corkscrew simulations were run for 16.4 µs, 
13.8 µs, 16.6 µs and 15.2 µs, respectively.  RMSDs in Figs. 1E and S7 were calculated 
on the hydrophobic core of the corkscrew (Cα atoms of residues 3 to 9, excluding the 
chains at the end). 
 
SOD1 oligomer assembly simulations were initiated from three monomers of a tandem 
repeat structure (KVKVWGSIKGL--GG--KVKVWGSIKGL) built in homology to a 
monomer of the tandem repeat structure of αB crystallin cylindrin (PDB ID 3SGR (12)).  
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These monomers were separated in space by at least 30 Å, placed in a box 62 Å on each 
side, and solvated with approximately 7,600 water molecules and 150 mM NaCl.  System 
preparation and simulations then proceeded as described above for the SOD1 corkscrew 
simulations.  Each monomer was weakly restrained such that its Cα root-mean-square 
deviation (RMSD) was within approximately 2 Å of the starting structure.  In particular, a 
flat-bottom harmonic restraint, U, was applied to each monomer such that 𝑈 𝑅 =
!! 𝑘(𝑅 − 𝑅!)!  for 𝑅 > 𝑅! , and 𝑈 𝑅 = 0 otherwise.  Here, 𝑅  is the RMSD from the 
initial structure, 𝑅! = 2 Å, and 𝑘 = 50 kcal mol-1 Å−2.  The flat-bottom RMSD restraints 
limit the monomers’ sampling of very collapsed structures and structures that have 
significantly reduced β-sheet content, and allow simulations to focus on discovering 
possible amyloid-like oligomers.  We ran 20 assembly simulations beginning from the 
same starting conformation with different initial velocities drawn from a Maxwell-
Boltzmann distribution.  Of the twenty simulations, four were run for 4 µs and the rest 
were run for 1 µs. 
 
The αB crystallin assembly simulations were initiated from three monomers of the 
tandem repeat structure of αB crystallin (GKLKVLGDVIEV--GG--KLKVLGDVIEV, 
PDB ID 3SGR).  System preparation and simulation protocol were as above, except that 
we ran 10 assembly simulations in this case. Of these 10 simulations, two were run for 
5 µs, two were run for 2 µs, and the rest were run for 1 µs. 
 
Expression and purification of SOD1 constructs  
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All SOD1 constructs were expressed recombinantly using an E. coli system. All 
recombinant proteins are based on a SOD1 background strain that carries a C6A, C111S 
double mutation to simplify the purification. The SOD1 gene was inserted into the 
pET22b vector from Novagen with NcoI and SalI restriction enzyme digestion sites (gift 
from Professor Joan Valentine’s lab at UCLA).  Mutations in the SOD1 gene were made 
using the QuickChange Site-Directed mutagenesis Kit (Stratagene). The plasmid was 
transformed into the BL21(DE3)Gold (Agilent Technologies) expression strain. For 
expression, 10 ml LB + Amp (50mg/mL) was inoculated from frozen stock and grown 
overnight. 10 ml of starting culture was added to a 2L flask of 1L LB + Amp (50µg/mL) 
and grown for 3 hours at 37 °C to OD600 = 0.6. IPTG was then added to 1 mM and Zn2+ 
was added to 0.05 mM to induce protein expression, which continued for an additional 3 
hours. The bacterial pellet was collected by centrifugation at 4000 rpm for 10 mins. 
 
To purify SOD1 from the bacteria, osmotic shock was used to release proteins including 
SOD1 from the periplasm. First, the cell pellet was resuspended in 30 mL of 30 mM Tris-
HCl pH 8 with 20% sucrose and stirred slowly for 20 mins. The cells were collected by 
centrifugation at 10,000 × g at 4°C for 10 mins. The pellet was then resuspended in 30 
mL of ice-cold water and stirred slowly for 20 mins on ice to release periplasmic proteins. 
Next, cell debris was removed by centrifugation at 4°C for 10 mins at 10,000 × g. The 
contaminant proteins were then removed by precipitation with ammonium sulfate. 0.326 
g/ml (NH4)2SO4 was added to the supernatant, and the solution was stirred at 4°C for 45 
mins. The protein was purified out of ammonium sulfate by separation over a phenyl 
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sepharose column. The column was equilibrated with buffer A (2 M (NH4)2SO4, 0.15 M 
NaCl, 0.05 M KH2PO4, pH 7.0, adjusted with 1 M KOH) and buffer B ( 0.15 M NaCl, 
0.05 M KH2PO4, pH 7.0, adjusted with 1 M KOH). The protein eluted at 6-30% buffer B. 
The protein was then concentrated and further purified by size exclusion chromatography 
on a silica G3000 column (Tosoh Bioscience). The column buffer comprised 0.1 M 
sodium sulfate, 25 mM sodium phosphate, and 1 mM sodium azide, pH 6.5. 
 
SOD1 demetallation (required for aggregation) 
The protein constructs purified by size exclusion chromatography were dialyzed in four 
buffers at 4°C to remove the bound metals. Protein preparations were put in a 10 kDa 
dialysis cassette and exchanged against buffer 1 twice (100mM Na Acetate pH 3.8, 
10mM EDTA pH 8.0), followed by dialysis in buffer 2 (100mM Na Acetate pH 3.8, 
100mM NaCl), buffer 3 (100mM Na Acetate pH 5.5, 100mM NaCl) for 4 hours, and 
finally in buffer 4 (20mM K phosphate pH7.0) for 12 hours each. To avoid metal 
contamination, all stock solutions (except for EDTA) were treated with Chelex 100 resin 
(Bio-Rad) to remove trace metals and all beakers were rinsed with metal-free water. 
 
Protein and peptide aggregation 
 
Full-length SOD1: Following metal removal, proteins were concentrated with a 10kDa 
concentrator to 800 µM (monomer) stock concentration and stored at -80 °C in 50µL 
aliquots until further use. Aggregation assays were carried out in 1.5 mL 
microcentrifuge tubes (Fisher Scientific) under acidic conditions with 80 µM SOD1, 
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50 mM sodium acetate, 1 mM EDTA and 1 mM TCEP, pH 3.5. Preparations were 
agitated at 900 rpm at 37 °C for indicated times. These samples were then dialysed 
with 10 mM potassium phosphate and 1 mM EDTA, pH 7.0 for 4 hours at 4 °C. 
 
Peptide: Peptide segments were aggregated by incubation at 37°C for 12 hours with 
agitation in 50 mM tris-base buffer and added to cultured neurons. 
 
Differentiation of mESCs to motor neurons  
Hb9:eGFP mESCs were maintained and differentiated into motor neurons as previously 
described (13). Briefly, mESCs were first plated on gelatin to remove mouse embryonic 
fibroblasts (MEFs) prior to differentiation, and then plated in 60 mm bacterial petri dishes 
in core motor neuron medium (DMEM/F12, Neurobasal, 10% Knockout Serum 
Replacement, Pen-Strep, Glutamax) to induce embryoid body (EB) formation. Two days 
later, N2 supplement (1x), retinoic acid (1 µM; Sigma), and SAG (1 µM; Calbiochem) 
were added to the EBs. Media was changed every two days. After five days post-retinoic 
acid and SAG addition, Hb9:GFP EBs were dissociated using ice-cold 0.25% Trypsin-
EDTA for 6 minutes at room temperature, followed by trituration in L-15 medium 
(Hyclone). Dissociated motor neurons were plated in core motor neuron medium with 
GDNF, BDNF, CNTF (all 10 ng/ml; Peprotech) on 96-well plates that were previously 
coated with poly-L-ornithine (0.01%; Sigma) and laminin (5 µg/ml; BD Biosciences) and 
incubated for 12-16 hrs before treatment with the SOD1 peptides or proteins. 
Approximately 80,000 cells were plated per well. All reagents are from Invitrogen, unless 
otherwise noted. 
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Cytotoxicity Assays 
Peptide segments were dissolved in 50mM Tris (base) and aggregated by incubation at 
37°C for 12 hours with agitation and then added to cultured neurons at the given final 
concentration. Unless stated otherwise, all full-length proteins were aggregated for 12 
hours before adding to motor neurons at 8 µM final concentration. Motor neurons were 
incubated for 12-16 hrs and imaged (Axio Observer.D1 microscope, Zeiss), followed by 
cell viability assay. Cell viability was measured using the commercially available MTT 
assay (Promega Cat#G4100) according to the manufacturer’s protocol with 4 hour 
incubation with the MTT reagent. All data were normalized using buffer as 100% 
viability and 0.2% SDS as 0% viability. Experiments were performed in triplicates and 
repeated a minimum of three times. 
 
Electron Microscopy 
3-5 µL sample was spotted directly on freshly glow-discharged carbon-coated electron 
microscopy grids (Ted Pella, Redding, CA). After 4 min incubation, grids were rinsed 
twice with 5µL distilled water and stained with 5µl of 2% uranyl acetate for 1 min. 
Excess uranyl acetate was removed by blotting and specimens were examined on a T-12 
electron microscope at an accelerating voltage of 80 kV. Images were recorded digitally 
by wide angle (top mount) BioScan 600W 1 × 1K digital camera (Gatan, Pleasanton, 
CA). 
 
Dot Blot Assay  
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3-5µL sample was spotted on a nitrocellulose membrane (Trans-Blot, Bio-Rad) followed 
by blocking with 10% fat-free milk in 1X TBST buffer (50 mM Tris, 150 mM NaCl, 
0.05% Tween20) for 30 mins. Membranes were incubated with primary antibody – 
SOD100 (Enzo Life Sciences) at 1:1000 dilution, SODAb (gift by Prof. David Borchelt) 
at 1:5000 dilution, A11 (EMD Millipore) at 1:500, CSAb (in-house) at 1:500 diluted in 
5% fat free milk in TBST buffer at room temperature for 1 hour. The membranes were 
washed three times in TBST buffer before incubating with HRP-linked secondary 
antibody - anti-mouse HRP secondary antibody (Life Technologies) at 1:10000 dilution, 
or anti-rabbit HRP secondary antibody (Life Technologies) at 1:10000 diluted in 5% fat-
free milk in TBST buffer at room temperature for 1 hour. Pierce ECL Western Blotting 
Substrate, (Thermo Scientific, #32209), a chemiluminescent substrate was used for the 
detection of horseradish peroxidase (HRP) on the immunoblots following the 
manufacturer’s instructions. Detailed protocol can be found on 
https://tools.thermofisher.com/content/sfs/manuals/MAN0011536_Pierce_ECL_West_Bl
ot_Subs_UG.pdf 
 
Thioflavin-T (ThT) Assay 
Fibril formation assays were performed with 80 µM protein concentration in 50 mM 
sodium acetate buffer, 1 mM EDTA, 1 mM TCEP, pH 3.5 and 10 µM ThT – conditions 
identical to those used for aggregating proteins for the cytotoxicity assays, but with the 
addition of ThT. All assays were carried out in black Nunc 96-well optical bottom plates 
(Thermo Scientific). Plates were agitated at 300 rpm in 3-mm rotation diameter in a 
Varioskan microplate reader (Thermo) at 37 °C. Fluorescence measurements were 
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recorded every 30 mins using λex = 444 nm, λem = 482 nm, with an integration time of 
200 µs.  
 
Mass Spectrometry  
Peptide segments were dissolved in 20 mM ammonium acetate buffer (pH = 7) to the 
final concentration of 200 µM and incubated at room temperature without any agitation. 
Experiments were carried out at time t0 and every day for a week and ion mobility was 
used to calculate the cross sections of oligomers. The peptide samples were nano-
electrosprayed on a home-built, high-resolution ion mobility mass spectrometer (14) 
consisting of a source ion-funnel, a two-meter long drift cell, an exit funnel, a quadrupole 
mass analyzer and detectors. The ions were stored and focused in the source funnel and 
subsequently pulsed into the drift cell filled with helium gas at high pressure. A drift 
voltage was applied across the cell to create a weak electrical field. The ions moved 
forward under the influence of the electrical field, and at the same time experienced the 
drag force due to multiple collisions with helium buffer gas. An ion traveled with a 
constant velocity that reflected its size and shape. At the end of the drift cell, the ions 
were collected by an exit funnel where they were steered and focused into a quadrupole 
mass analyzer and detected as a function of arrival time in the arrival time distributions 
(ATDs). By measuring ATDs at different pressure to voltage (P/V) ratios, the absolute 
mobility of the ion of interest could be measured: 
𝑡! = 𝑙!𝐾! 273.16 𝐾760 𝑡𝑜𝑟𝑟 ∙ 𝑇 ∙ 𝑃𝑉 + 𝑡! (𝐸𝑞. 1) 
 57 
In Eq. 1, 𝑙 is the length of the drift cell, P is the gas pressure in torr, V is the voltage 
across the cell, and t0 is the time the ions spend outside the drift cell before reaching the 
detector. The collision cross section 𝜎 can then be approximated from K0 (15) 
𝜎 ≈ 3𝑞16𝑁 2𝜋𝜇𝑘!𝑇 !! 1𝐾!  (𝐸𝑞. 2) 
Here, N is the buffer gas density, µ is the reduced mass of the collision system (He+ion) 
and kB is Boltzmann’s constant. The cross section contains information about the three 
dimensional structure of the ion. In the ATDs shown in Fig. S8, underneath each 
experimental peak is a dotted line representing the peak shape expected for a single 
conformer (16) . 
 
Zebrafish 
All zebrafish (Danio rerio) were maintained in accordance with standard laboratory 
conditions (17). The University of California, Los Angeles (UCLA) Chancellor's Animal 
Research Committee approved all experiments performed on zebrafish. The TDL6 
(Tübingen driver line) zebrafish used in all experiments were identified in a screen for 
developmentally regulated enhancers that drive tissue-specific expression.  Gal4-driven 
GFP expression marks primary motor neurons. Mitochondria were marked by a TOL2-
mediated insertion of a Gal4-UAS-MLSDsRed construct (18). 
 
RNA production and injections 
SOD1 constructs used for zebrafish expressions were the full-length sequence with Cys6 
and Cys111 intact. The constructs (WT, G93A, G93A/G33V, A4V, A4V/G33V were 
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subcloned into pcGlobin2 vector and the constructs were linearized using XbaI to 
generate RNA. The Translation efficiency of the RNA of all constructs was tested by 
TnT® Quick Coupled Transcription/Translation System (Promega) using the 
manufacturer’s instructions. Construct G93A/G33V has an additional mutation of I18G 
to prevent steric clashes due to the presence of G33V in the native SOD1 barrel. As a 
control we also tested the cytotoxicity of this construct in cell culture and found that it 
was non-toxic similar to G33V construct (Fig. S15B). RNA was transcribed using the 
mMessage Machine T7 kit (Ambion) and the mRNA was diluted to 500 ng/µL and 1000 
ng/µL aliquots and stored at -80°C. 1 µL mRNA at 500 ng/µL (WT, G93A, G93A/G33V) 
and at 1000 ng/ µL (WT, A4V, A4V/G33V) was injected into TDL6 embryos from timed 
mating at the 1-4 cell stage. Embryos were incubated in 1x E3 buffer at 28.5 °C. 
 
Analysis of axonopathy 
At 2dpf zebrafish larvae microinjected with SOD1 constructs were anesthetized in 0.01% 
tricaine and imaged using a Leica MZ16F fluorescent stereoscope at 11.5X 
magnification. Observers were blinded and the length from the exit point of the spinal 
cord to the tip of the motor axon was measured for 5 axons per embryo corresponding to 
axons 12-16 using Fiji Simple Neurite Tracer. Experiments were repeated a minimum of 
three times and a total of 72 embryos were assessed for each construct. 
 
Analysis of mitochondrial network 
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The mitochondrial network from the base of the spinal cord to the tip of the motor axon 
was imaged on a Leica TCS SP8 confocal microscope at 10X magnification with a 1.5X 
optical zoom. Images were processed with the Leica AF software and mitochondria size 
was measured for 5 axons per embryo using Fiji Image J Particle Analysis with the 
described algorithm (19). Before quantification, fluorescence from the spinal cord and 
regions outside of the larvae body were excluded. The program allowed automatic 
detection of isolated fluorescent spots by threshold and watershedding of binary 
formatted images without introducing user-bias. Spots with a circularity of 0.5-1 were 
selected to have their intensity and area quantified, where 1 is a complete circle. Intensity 
was quantified for each spot via overlapping gray levels and is reported as number of 
mitochondria as previously reported (20).  
 
Protein expression in zebrafish 
 
Protein expression was confirmed by western blotting (Fig. S15). Zebrafish embryos 
were pooled from each group at 2dpf and washed twice in Ringer’s buffer (NaCl 135mM, 
KCl 5mM, MgSO4 1mM, K2HPO4 0.4mM, Glucose 5.5mM, HEPES 20mM pH 7.4). The 
embryos were subsequently deyolked, dechorionated and lysed in RIPA buffer (Sigma) 
(volume equals twice the number of embryos in µL) with Halt protease inhibitor cocktail 
EDTA-free (Thermo Scientific) added. Lysates were homogenized by sonication and 
protein concentration was determined using the BCA protein assay kit (Thermo Fisher 
Cat #23252). Equal amounts of protein were loaded on 12% Tris-glycine PAGE gels and 
transferred onto a PVDF membrane using an iBlot dry blotting system (Thermo Fisher) at 
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20V for 6 mins. Membranes were washed with methanol followed by water and then 
blocked with 10% fat free milk in TBST for 1hr at room temperature and washed three 
times with TBST buffer. Membranes were incubated with primary antibodies – SOD100 
(Enzo Life sciences) at 1:500 dilution in 5% milk in TBST and incubated for 1hr at room 
temperature or anti β-actin (Abcam) at 1:1000 diluted in 5% milk in TBST and incubated 
overnight at 4°C. Membranes were first probed with SOD100 and then stripped using 
Restore PLUS Western Blot stripping buffer (Thermo Scientific) and subsequently 
probed with anti β-actin. Blots were washed thrice with 1X TBST and subsequently 
incubated with the secondary anti-rabbit HRP secondary antibody (Sigma) at a 1:2500 
dilution in 5% milk in TBST for 1hr at room temperature. Pierce ECL Western Blotting 
Substrate, (Thermo Scientific, #32209), a chemiluminescent substrate was used for the 
detection of horseradish peroxidase (HRP) on the immunoblots following the 
manufacturer’s instructions. 
 
Antibody generation 
Mice were immunized with 10 µg of synthetic peptide KVKVWGSIKGL dissolved in 
PBS and incubated 12 hours at 4°C. Boosts were performed bi-weekly for 4-8 weeks with 
the same dosages.  Mice were sacrificed and splenocytes were fused with Sp2/0 myeloma 
cells (American Type Culture Collection cell line CRL-1581, Manassas, VA) (21). 
Following HAT selection, surviving clones were cultured in microwell plates and 
selected for production of IgG binding to peptide KVKVWGSIKGL. These screens were 
performed by indirect ELISA on culture supernatants and confirmed by dot blots with 
KVKVWGSIKGL peptide bound to nitrocellulose. Monoclonal antibody (MAb) CSAb 
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was identified by these criteria and the clone was stabilized by limiting dilution 
subcloning. MAb was produced from bulk hybridoma culture in medium with serum 
depleted of bovine IgG and purified by Protein G chromatography (Pierce Biotechnology, 
Rockford, IL).   
 
Blue native gel electrophoresis 
Samples were prepared by mixing with 4X NativePAGE sample buffer. For more details 
refer to the protocol for the Novex Native PAGE Bis-Tris Gel System (Thermo Fisher) 
(https://tools.thermofisher.com/content/sfs/manuals/nativepage_man.pdf). Briefly, equal 
amounts of proteins were loaded on 3-12% Bis-Tris native gels with light blue cathode 
buffer at 150 V for 2 hours. The protein was transferred to PVDF membranes using iBlot 
dry blotting system (Thermo Fisher) at 20V for 6 mins. Membranes were washed with 
methanol to remove Coommassie Blue and then washed with water. Membranes were 
then blocked with 10% fat-free milk in TBST for 1 hour at room temperature. 
Membranes were then washed three times with TBST and incubated with the primary 
antibody – SOD100 (Enzo Life Sciences) at 1:1000 dilution or CSAb (in-house) diluted 
1:500 in 5% fat-free milk in TBST for 1 hour. Membranes were then washed with TBST 
three times and incubated with the secondary antibody – anti-mouse HRP secondary 
antibody (Life Technologies) at 1:10000 dilution or anti-rabbit HRP secondary antibody 
(Life Technologies) at 1:10000 dilution in 5% fat-free milk in TBST). Membranes were 
washed again three times with TBST and the films were developed following the 
protocol as described in the Kit (Thermo Scientific Pierce ECL Western Blotting 
Substrate, #32209).  
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Immunohistochemistry 
Slides were deparaffinized by xylene followed by a series of washes in ethanol. After a 
wash under tap water, the slides were incubated in 3% hydrogen peroxide in methanol for 
10 minutes. The slides were washed with distilled water and incubated for 10 minutes in 
EDTA Solution pH 8 (Invitrogen, #005501) at 95°C using a vegetable steamer. 
Following cool down to room temperature and washing with PBST (phosphate buffered 
saline containing 0.05% Tween-20), the slides were incubated at room temperature for 2 
hours with anti-mouse CSAb antibody diluted 1:100 followed by Post Primary reagent of 
the Bond Refine Polymer Detection Kit (Leica, DS9800), for 30 minutes. Slides were 
rinsed with PBST and incubated with the Polymer reagent of the Bond Refine Polymer 
Detection Kit (Leica, DS9800), for 30 minutes, followed by incubation with DAB (3,3'-
Diaminobenzidine) for visualization. Slides were counterstained with Harris’ 
Hematoxylin, dehydrated in ethanol, and mounted with media.  
 
Statistical Significance 
All statistical analyses were done using GraphPad Prism 7.0.  
 
Antibodies used 
 
The following antibodies were used in this study. SOD100 (EnzoLife sciences) at 1:1000 
dilution, SODAb (gift by Prof David Borchelt) at 1:5000 dilution, A11 (EMD Millipore) 
at 1:500 dilution, anti β-actin (Abcam) at 1:1000, CSAb (in-house) at 1:500 dilution, anti-
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mouse HRP secondary antibody (Life technologies) 1:10000 dilution, anti-rabbit HRP 
secondary antibody (Life technologies) 1:10000 dilution. 
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Supplementary Text 
Prediction of oligomer forming segments in SOD1 
 
Several reports have suggested that oligomers formed by amyloid proteins have a pore or 
barrel shape and are composed of anti-parallel β strands (22, 23). To investigate segments 
in SOD1 that may be critical for oligomer formation, we applied a combination of 3D-
profiling and manual sequence fitting using a model of anti-parallel β sheet structure that 
we had previously discovered termed cylindrin (12) (Fig. S2). In order to predict which 
11-residue segments of SOD1 might form a cylindrin-like structure, we analyzed the 
cylindrin structure by visual inspection and computational modeling.  We examined the 
structural features of the native cylindrin, and compared these with cylindrin models of 
segments from other proteins.  Our analysis followed three stages: 
 
1. Computational prediction of cylindrin-compatible segments by 3D profiling 
Using a process analogous to our 3D profile method for predicting steric-zipper-forming 
segments (24), we used the Rosetta modeling suite (25) for high-throughput 
computational modeling and prediction of cylindrin-forming segments (Figure 
S2A).  Starting from the 6-stranded cylindrin barrel structure (from PDB 3SGO), we 
stripped off all side-chain atoms, then threaded on each 11-residue sequence segment of 
several amyloid proteins (The same 11-residue sequence segment was threaded onto each 
of the six strands of the cylindrin.).  Side chains matching the amino acid sequence of the 
segment being threaded were attached to the backbone and repacked; this selects an 
energetically favorable rotamer at each position. The backbone was then randomly 
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perturbed by small sub-Angstrom moves, followed by repacking for up to 1000 iterations, 
or until energetic convergence.  We then used the final, minimized Rosetta energy scores 
to rank the threaded protein segments—those with the lowest energy show the best 
compatibility with the cylindrin structure.  The default Rosetta energy function 
(Talaris2013) was used.  
 
2. Analysis of computational predictions and visual comparison with the native cylindrin 
Among the lowest-energy computational predictions, one sequence feature immediately 
stood out – glycine at position 6.  A closer look at the native cylindrin structure revealed 
why: glycine’s lack of side chain provides room for the adjacent, inward-facing valine 
side chains (at position 4) to pack.  As shown in Figure S2C, unrolling the cylindrin 
barrel to view the interior surface reveals a series of ‘knobs’ (valine 4 side chains, cyan) 
that can pack into ‘holes’ (green) provided by glycine.  Without these glycine ‘holes’, the 
interior of the barrel would be too full, forcing the β-strands apart.  A swap in the 
positions of knobs and holes (that is, moving glycine to position 4, and valine to position 
6) might also be expected to allow the barrel to close. However, the computational 
modeling never gave low scores to segments with swapped knobs and holes. The reason 
we found is that the cylindrin backbone torsion angles at position 6 favor glycine. 
 
Our analysis of the cylindrin’s interior packing also highlighted the importance of the 
other inward-facing side chains, which pack in symmetric layers (Figure S2B).  From the 
center, and moving outward, these are valine 4, valine 8, and valine 2.  The valines form 
a hydrophobic core, which together with hydrophilic side chains on the exterior, likely 
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promote assembly of the cylindrin. Based on these observations, our expectation was that 
good candidates for cylindrin formation would have three features: (1) a glycine at either 
position 4 or 6; (2) segregated hydrophobic and hydrophilic residues, in inward- and 
outward-facing positions, respectively; and (3) appropriately sized inward-facing 
residues, to optimize packing in the small interior of the barrel. 
 
We therefore went on to analyze the predicted structures of the lowest-energy models, to 
see whether our expectations matched the computational predictions. As mentioned 
above, all of the lowest-energy segments had glycine at position 6. Regarding segregation 
of hydrophobic and hydrophilic residues, there was no clear pattern.  Some low-energy 
segments were nearly completely hydrophobic. Others had polar, or even charged, 
residues positioned in the interior.  Some of these polar residues, such as asparagine, 
were positioned to largely fulfill potential hydrogen bonds. Others, such as serine and 
histidine, were generally not able to hydrogen bond with adjacent side chains, suggesting 
their segments are unlikely to form a cylindrin.  We concluded that while Rosetta seemed 
well-able to handle steric considerations when packing side chains, it had more difficulty 
handling charge and hydrogen-bonding considerations. 
 
The sizes and shapes of interior side chains in low-energy models fit better with our 
expectations. Valine, and similarly sized side chains like threonine and isoleucine, packed 
quite well (Figure S2D). Slightly larger side chains of methionine and histidine also fit 
(Figure S2E, F). Even larger side chains, such as phenylalanine, tyrosine, and tryptophan, 
were absent in top-scoring segments. Side chains smaller than valine, such as alanine, 
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serine, and even glycine, also came out in top-scoring segments (Figure S2G, H).  
Although these did not give rise to steric clashes, they did leave visible gaps in the 
interior, which we hypothesized would be less favorable than if the holes were filled 
(similar to the original cylindrin).  
 
3. Manual selection of cylindrin-compatible segments 
Although the 3D profile method provided a number of reasonable predictions, there were 
enough deviations from our expectations that we also performed a manual search for 
cylindrin-compatible segments (Figure S2I).  We began by casting a wide net, using a 
sequence-based search to pull out any segments that matched either a basic pattern found 
in the cylindrin core sequence or in variations that we predicted were possible (for 
example, swapped ‘knob’ and ‘hole’ positions).  Adjacent to the glycine ‘hole’, we 
restricted possible ‘knob’ residues to five: valine, isoleucine, leucine, methionine, and 
threonine.  Sequences matching at least one of these basic patterns were then screened for 
clearly unfavorable features at other positions, and removed accordingly. 
 
From an initial group of 143, 11-residue segments spanning the full sequence of SOD1, 
our screen yielded 4 overlapping sequences from the N-terminal region: segments 28-38, 
30-40, 32-42, and 34-44. One of these, 32-42, was also predicted by our computational 
threading. A re-examination of the 28-38 segment showed that the small backbone 
movements allowed in our computational threading could not relieve a clash between the 
proline at position 1 and the position 11 leucine of the neighboring strand, without 
breaking apart the structure. As mentioned above inward facing glycines are critical for 
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the hydrophobic packing. Among the 4 segments, 28-38 was the only segment with 
glycine at position 6 that is conserved in ALS patients and contains a central stretch of 
amino acids that are conserved in ALS patients (Fig. S3). Interestingly, the segment has 
also been found to be prone to local unfolding by H/D exchange and mass spectrometry 
studies and small molecule inhibitors of aggregation are found to bind this segment (26–
28).  Keeping these reports in mind, the segment 28-38 was chosen for further 
characterization. 
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Mass assignment by ion-mobility mass spectrometry (IM-MS)  
 
A detailed experimental workflow for IM-MS experiments has been described elsewhere 
(29, 30). In this experiment, the ions were generated by n-ESI, stored in an ion-funnel, 
and subsequently pulsed into a drift cell filled with helium gas at P = 13 torr. The ions 
were moving through the drift cell toward the quadrupole mass analyzer under the 
influence of both a weak electrical field and a drag force caused by collisions with buffer 
gas. For the same oligomer with different conformations, those that are more extended 
will experience more collisions with the buffer gas, thus travel slower than those that are 
more compact. For oligomers with different sizes, species with higher charges are 
affected more by the electrical field (‘drift’ voltage) and travel faster than species with 
smaller charges. For example, a dimer with z = +2 charge will travel faster than a 
monomer with z = +1 charge, and the ATD (arrival time distribution) feature 
corresponding to the dimer will have a shorter arrival time than that of the monomer (31). 
By measuring the arrival times at different pressure to drift-voltage ratios, experimental 
collision cross sections can be measured for all features in the ATDs. The values can be 
compared to the cross sections obtained from theoretical modeling and x-ray 
crystallography. 
 
The mass spectra of the cylindrin and corkscrew forming peptides are shown in Figure 
S8, panels A and B. Despite the difference in charge states in solution, major peaks with 
n/z = +1/2, +2/3, +1/1 and +5/4 were observed in the mass spectra for both peptides. 
SOD1(28-38) has additional peaks of n/z = +1/3 and +3/4. In addition, since SOD1(28-
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38) is highly charged, salt-adduct peaks are also observed, which are absent in the mass 
spectra of the cylindrin segment. 
 
We focused our analysis on the n/z = 1/1 mass spectral peaks of both segments since they 
contain multiple features that may correspond to large oligomers. First, we analyzed the 
ATD of the cylindrin segment, which has been shown to form hexamers by x-ray 
crystallography. The ATD shows multiple features (Fig. S8A), and we can 
unambiguously identify the monomer (σ = 268 Å2) and dimer (σ = 440 Å2) at 108.95 and 
90.40 ms, respectively. The z = +1 monomer observed at this ATD has a similar cross 
section to z = +2 monomer at 599 m/z (σ = 263 – 274 Å2, data not shown). Similarly, the 
cross section of z = +2 dimer is similar to z = +3 dimer at 799 m/z (σ = 442 – 452 Å2, 
data not shown). The next peak at 85.5 ms is assigned a trimer with σ = 625 Å2, as it does 
not fit a dimer. The spacing between the 75.75 ms peak and its adjacent peak at 85.5 ms 
(10.2 ms) is much larger than the spacing between dimer and trimer (4.85 ms). Thus, it 
cannot be classified as a tetramer and fits a hexamer with a cross section of 1122 Å2. To 
resolve the size of the peak at 69.65 ms, we compared the mass spectra at different time 
points. The ATD of cylindrin after 24 hours shows a rearrangement in the peaks (Fig. 
S8D). The dimer and trimer peaks are essentially gone, while the hexamer peak at 75.75 
ms is relatively unchanged. The peak at 69.65 ms increased in intensity, and no further 
peaks at shorter times have appeared. Hence the 69.65 ms peak is most likely the terminal 
stable soluble oligomer. The best assignment for the 69.95 ms peak is a compact hexamer 
with a cross section of 1020 – 1023 Å2. If we use the X-ray coordinates of the cylindrin, 
we obtain a cross section of σav = 1029 Å2 (σav is the average cross section obtained from 
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the trajectory and projected superposition approximation methods) (30, 32, 33), in 
excellent agreement with this assignment. Thus, it appears there are two stable hexamers 
of cylindrin, one open and one compact. 
 
Next, we analyzed the mass spectra of SOD1(28-38). In this case, the n/z = 1/1 mass 
spectral peak initially appears to have a single, broad feature as its ATD (Fig S8E). After 
24 hours, a more intense ATD is observed and now two features are resolved (Fig. S8F). 
Given our results for the cylindrin segment discussed above, the arrival times of these 
two features correspond to open (1189 Å2) and compact (1113 Å2) hexamers. The X-ray 
coordinates of SOD1(28-38) yield a cross section of σav = 1182 Å2 that increases to 1226 
Å2 after 20-ns of MD relaxation, in good agreement with the experiments. Similar to the 
cylindrin segment, the terminal species appears to be a hexamer for SOD1(28-38). In 
addition, the compact feature in the ATD is broad suggesting numerous “cylindrin-like” 
structures. If we thread the sequence of SOD1(28-38) on the backbone of the cylindrin 
structure, we obtain a cross section of 1107 Å2, which is near the σav = 1113 Å2 
experimental cross section calculated above. This calculation supports our assignment of 
the broad peak centered near 74 ms as a compact, cylindrin-like hexamer. Thus, in 
solution, SOD1(28-38) segment forms oligomers similar in cross section to the observed 
crystal structure of the corkscrew and a more closed, cylindrin-like structure. 
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Supplemental figures: 
 
Fig. S1. Discovery of a cytotoxic segment of SOD1. Starting from the cylindrin 
backbone structure, sequences of SOD1 were examined for structural compatibility. The 
segment SOD1(28-38) was found to be compatible, and was put into crystallization trials, 
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and the atomic structure was determined. The significance of the structure to SOD1-
linked cytotoxicity was then tested by introducing mutations designed to disrupt the 
structure. 
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Fig. S2. Prediction of cylindrin-compatible segments 
 80 
(A) 3D profile method for predicting cylindrin-compatible segments in amyloid proteins.  
An example of threading with the amyloid-β peptide is shown. 
(B,C) Visual analysis of the cylindrin structure revealed a layering of side chains in the 
core (B; backbone shown as a line, with even-numbered, ‘inward-facing’ side chains 
shown as sticks, and glycine Cα shown as a small sphere), and a 'knob in hole' packing of 
valine and glycine residues (C; surface rendering) that allows for the small circumference 
of the barrel. 
(D-H) Structures resulting from the 3D profile predictions were analyzed for packing in 
the barrel core. Representation is similar to panel B, but with side-chain atoms 
represented by spheres with van der Waals radii.  The protein of origin and segment 
sequence are given, with even-numbered, ‘inward-facing’ residues in bold, and the 
critical position 4 residue underlined. (D) The original cylindrin structure, after Rosetta-
based side-chain repacking and energy minimization.  Notice the packing of valine 4, 
cyan, near the center. Although there is a gap between the two layers (arrowhead), it is 
small.  (E) In this model of a segment from the human prion protein, methionine (cyan) 
occupies the central position 4, filling the space more than valine of the cylindrin 
sequence.  (F) A histidine side chain at position 4 can also fill the central space, but is not 
able to satisfy hydrogen bonding groups. (G) Alanine at position 4 does not fill the core 
as well, leaving gaps (arrowheads). (H) Adjacent alanine and glycine, at positions 2 and 8 
respectively, leave large gaps in outer layers of the cylindrin model core (arrowheads), in 
spite of a native valine packing in the middle at position 4. 
(I) Manual selection of cylindrin-compatible segments.  First, three sequence-based 
criteria, which define the glycine position and the position of an adjacent, appropriate 
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side chain (with cylindrin-compatible size and charge) in the core, were used in the initial 
selection of segments.  The resulting sequences were further culled based on the presence 
of undesirable amino acids in specific positions.  Prolines were avoided because of their 
tendency to disrupt β-structure.  Charged and bulky inward-facing residues were avoided 
because of likely disruption to the packing.  Small inward-facing residues were avoided 
because of gaps in packing, e.g. as in panel H Large numbers of glycines were avoided 
because of the tendency for these sequences to be flexible rather than adopt a fixed 
conformation. Cysteines were avoided for experimental purposes. Four overlapping 
segments of SOD1 resulted from this manual selection.  
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Fig. S3. Frequency distribution of ALS-related mutations in SOD1. (A) Histogram 
representation of the number of familial-disease mutations found at each residue position. 
Gray connected line refers to the total number of patients known to carry mutations at 
that residue. The segment 28-38 is expanded. Val29 and Val31 each have one known 
familial mutation and Gly37 and Leu38 have two known familial mutations. The segment 
from W32-K36 is currently the longest segment known to be unmutated in ALS patients. 
Notice that the segment 28-38 has low frequency of individuals with ALS linked 
mutations. A total of 4 individuals are known to carry mutations in this region. Data were 
obtained from http://alsod.iop.kcl.ac.uk  (B) Ribbon diagram of dimeric SOD1 (PDB ID: 
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2C9S) with the segment 28-38 highlighted in blue. Zinc and copper atoms are shown as 
magenta spheres, and the familial mutation residues, A4V and G93A are colored red.  
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Fig. S4. Surface map of the corkscrew crystal structure showing hydrophobic surface (in 
red) on the surface (left) and in the inner pocket (right) made up of valine, leucine, and 
isoleucine side chains. 
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Fig S5. Hydrogen bonding network of corkscrew is composed of alternate weak and 
strong interfaces similar to the cylindrin structure. (A) Hydrogen bonding network of 
the corkscrew structure. Shown here the orange β strand has a strong interface with the β 
strand below composed of 9 hydrogen bonds and a weak interface with the β strand 
above composed of 7 hydrogen bonds. (B) Hydrogen bonding network in the cylindrin 
structure (PDB ID: 3SGO) shares a similar architecture where the orange strand has a 
stronger interface with the β strand below composed of 12 hydrogen bonds and a weak 
interface with the β strand above composed of 8 hydrogen bonds. Br2 referes to the non-
natural amino acid 2-bromoallyl-glycine that was used for phasing. 
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Fig. S6. Mutation of lysine at position 28 contributes weakly to the crystal packing 
and not to the stability of the corkscrew structure (A) Crystal packing of the 
corkscrew structure. Two asymmetric units forming crystal contacts are shown in blue 
 87 
and yellow from neighboring corkscrews and N-terminal lysines are shown in sphere 
representation. Among the eight N-terminal lysines in each asymmetric unit, 5 form weak 
van der Waals interactions with (a) lysine residue and (b) tryptophan residue of the 
neighboring corkscrew. These interactions contribute weakly (~9%) of the total buried 
surface area in the crystal contacts. Buried surface area in the crystal contacts was 
calculated by AREAIMOL. (B) Lysine at position 28 is not essential for corkscrew 
formation and replacing it with the native proline residue does not disrupt the potential 
for hydrogen bonding. The N-terminal lysine forms a hydrogen bond with the serine of 
adjacent beta strand (Left). A PyMOL generated figure (right) shows that mutating the N-
terminal lysine to the native proline residue (gray) maintains the hydrogen bond.  
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Fig. S7. All-atom MD simulations of the corkscrew structure suggest that the G33W 
mutant structure is less stable than the wild-type glycine 33 structure in the context 
of the unmodified 28-38 segment, where residue 28 is a proline (PVKVWGSIKGL). 
The blue and red curves correspond to Cα root-mean-square deviations (RMSD) from the 
corkscrew crystal structure in MD simulations of the 8-chain wild-type 
(PVKVWGSIKGL) and G33W mutant (PVKVWWSIKGL) corkscrews, respectively. 
The G33W mutant deviates from the corkscrew structure, whereas the wild-type structure 
remains stable throughout the length of the simulation.  The simulations suggest that the 
dynamics of the backbone at residue 33 may contribute to the instability of the G33W 
mutant.  The G33 residue in the corkscrew structure occupies a region of Ramachandran 
space different from the allowable region for tryptophan and other non-glycine amino 
acids. In the wild-type simulations, the backbone dihedral angles of G33 tend to remain 
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in the lower right quadrant of a Ramachandran plot, whereas those of W33 in the mutant 
quickly relax to the beta-sheet/alpha-helix regions, leading to deviations from the 
corkscrew structure.  The extra hydrophobicity of G33W may also have an effect, making 
the mutant corkscrew more likely to collapse. 
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Fig. S8. The corkscrew-forming segment, SOD1(28-38) forms oligomers in solution 
with cross section similar to the crystal structure. (A, B) n-ESI-q mass spectrum of 
200 µM cylindrin and SOD1(28-38) peptides in 20 mM ammonium acetate buffer (pH = 
7.0), respectively. Each mass spectral peak is annotated with n/z where n is the oligomer 
number and z is the charge. (C-F) Representative ATDs of n/z = 1/1 peaks of the 
cylindrin and SOD1(28-38) peptides incubated for t = 0 and 24 hours. Each ATD feature 
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is annotated with n/z and an experimental collision cross section (M = monomer, D = 
dimer, Tr = trimer, Hex = hexamer). The narrow dashed lines are the peak shapes 
predicted for a single conformer of the cross sections given.  
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 Fig. S9. MD simulations indicate that the SOD1 segment (28-38) preferentially 
assembles into a corkscrew-like structure. (A) Weakly restrained monomers of SOD1 
spontaneously assembled into a corkscrew-like structure in MD simulation.  A snapshot 
of an assembled corkscrew-like structure from an MD simulation (red) is overlaid onto 
the crystal structure (blue).  Out of 20 simulations, three successfully assembled to a 
corkscrew-like structure.  Interestingly, in trajectories where a corkscrew did not form, 
individual monomers often formed interfaces comprised of out-of-register β sheets. (B)  
As a control, we found that monomers of αB crystallin spontaneously assembled into a 
cylindrin structure using the same simulation protocol. A snapshot of an assembled 
cylindrin from the MD simulation (red) is overlaid onto the crystal structure (blue, 
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PDB ID 3SGR).  Out of 10 simulations, one successful assembly to cylindrin was 
obtained.  As in the SOD1 assembly runs, in αB crystallin assembly trajectories where a 
cylindrin did not form we often observed dimers comprised of out-of-register β sheet 
interfaces.  See methods for additional simulation details.  
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Fig. S10. Electron microscopic characterization of the peptide samples assayed for 
cytotoxicity. All segments showed some short fibrils when aggregated at 1 mM in 50mM 
tris-base buffer for 12 hours with agitation. Although SOD1 segment (28-38) is cytotoxic 
but (28-38)G33V and (28-38)G33W are not, micrographs show no difference in fibril 
propensity. 
 
 95 
 
Fig. S11. Segment (28-38) with native proline is toxic and substitution at Gly33 
renders it non-toxic. (A) Peptides were prepared identically by solubilizing in 50 mM 
tris-base buffer and overnight incubation at 37 °C with agitation and ES-derived motor 
neurons were treated with 100 µM final concentration. P28(28-38) is toxic while the 
peptides with substitutions G33V and G33W are non-toxic. Symbols represent individual 
measurements and bars represent average values. Statistical significance was measured 
by one-way ANOVA. (*p < 0.05, **p < 0.01) 
(B) Electron micrographs of all three peptides showed similar sparse fibrils and thus 
substitution at Gly33 does not change the fibrillation propensity.  
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Fig. S12. (A) Representative electron micrographs of various preparations of the familial 
mutants A4V and G93A and the double mutants A4V/G33W and G93A/G33W. Some 
large aggregates can be seen at 2-16 hr time points but no fibrils whereas at 72 hours all 
constructs show large fibril loads. (B) Dot blots of the familial mutants aggregated for 
different time points. Samples aggregated for 12-16 hours are A11 positive and both 
proteins when aggregated for 72 hours lose A11 reactivity. SOD100 was used as loading 
control.  
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Fig. S13. WT and mutant SOD1 show similar kinetics of aggregation and 
cytotoxicity. (A) Thioflavin T assay of 80 µM WT protein shows a lag time of 2-4 hours 
before fibrils first appear (left). Cell viability (right) of ES-derived primary motor 
neurons incubated with protein aggregated for indicated times shows WT is only toxic 
when shaken up to 12 hours, when abundant fibrils first appear. (B) Similar to WT, the 
mutant G93A shows a lag time of 2-4 hours in a thioflavin T assay (left).  Cell viability 
(right) of ES-derived primary motor neurons incubated with protein aggregated for 
indicated times shows G93A is also toxic when shaken up to 12 hours, when abundant 
fibrils first appear. (C) Thioflavin T assay (left) shows G33W, the corkscrew-disrupted 
mutant protein behaves similar to WT and G93A with a lag phase of 2-4 hours. However, 
it is non-toxic at all time points (right). Results shown as Mean+SD (n=3). Statistical 
significance was analyzed using a two-tailed T-test with Welch’s correction (*P < 0.05, 
***P < 0.001, ns not significant). (D) Electron micrographs of SOD1 constructs 
aggregated for different lengths of time. Samples aggregated up to 12 hours tend to show 
no fibrils while samples aggregated for 16 hours or more show a large fibril load. Scale 
bar 200 nm.  
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Fig. S14. SOD1 aggregation pathway. SOD1 forms a stable dimer that is resistant to 
aggregation. Its destabilization into monomers renders it prone to aggregation into in-
register β-sheet rich fibrils. The corkscrew structure determined here, suggests that there 
is an off-pathway for oligomer formation independent of the in-register fibrils. The 
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mutations G33W and G33V specifically prevent corkscrew formation, an out-of-register 
oligomer. Fibril formation and cytotoxicity assays suggest that G33W and G33V do not 
affect the in-register fibril formation pathway and large fibrils are non-toxic.   
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Fig. S15. Expression of A4V and G93A mutant proteins causes axon shortening and 
mitochondrial clustering in zebrafish model. (A) Western blotting on zebrafish 
embryos to confirm expression of the mRNA injected. SOD100 was used to detect SOD1 
and β-actin was used as loading control. UI refers to uninjected zebrafish. (B) Construct 
G93A/G33V/I18G is non-toxic to ES derived motor neurons similar to the G93A/G33V 
mutant. Results shown as Mean + SD. Bars show average values and symbols represent 
individual measurements. Statistical significance was analyzed by one-way ANOVA (C) 
 102 
Zebrafish at 2dpf were imaged and higher percentage of A4V (30%) and G93A (10%) 
injected zebrafish displayed significant deformation compared to WT and the G33V 
expressing fish. (D) Average axon length (normalized to WT construct) and 
mitochondrial size of the different constructs. n refers to the total number of 
measurements made for each group.  
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Fig. S16. Electron micrographs of samples used for CSAb binding shown in figure 
4B, 4E. The corkscrew-forming segment SOD1(28-38) at 8 mM was incubated at 37°C 
for 12-16 hrs with and without agitation and probed for CSAb binding (Fig. 4E). The 
sample that showed no visible fibrils (top, left) was CSAb-positive, whereas the sample 
that was rich in fibrils (top, right) was CSAb-negative. Full-length apo-G93A protein at 
80 µM that was aggregated for 12 hrs with agitation was CSAb positive and did not have 
any fibrils (bottom, left) whereas the sample aggregated for 72 hrs that had abundant 
fibrils (bottom, right) was CSAb negative.  
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Fig. S17. CSAb does not recognize corkscrew-disrupting mutant protein. Proteins 
G93A, G93A/G33W, WT and G33W were aggregated for 2 hours and probed for CSAb 
reactivity. Both WT and G93A constructs showed aggregates by electron microscopy and 
were CSAb positive but G93A/G33W and G33W were not CSAb reactive. SOD100 was 
used to compare loading. 
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Fig. S18. CSAb reactivity in different ALS subjects. Micrographs of human ALS 
tissues probed for CSAb reactivity. (A) In 2 different SOD1-fALS patients we found 
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different reactivity patterns. In one subject, we found predominantly cytoplasmic 
reactivity in the gray matter. In another subject, we observed predominantly nuclear 
reactivity in non-neuronal cells in the gray matter. (B) In non-SOD1 linked fALS subjects 
we found both neuronal and non-neuronal reactivity. (C) In sALS subject, we observed 
reactivity in motor neurons but not in non-neuronal cells. (D) The specificity of the 
reactivity was measured by removing the primary antibody from the protocol. Scale bar 
of entire tissue sections (in A,B,C) 1000 µm and 20 µm of higher magnifications. 
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Table S1. X-Ray Data Collection and Refinement Statistics 
 
 KVKVWGSIKGL KVKVWGSIKGL (iodide) 
Beam line APS 24-ID-E APS 24-ID-E 
Resolution Å 1.9 2.1 
Total unique reflections  8378 11489 
Total reflections observed 47323 43500 
Space group P212121 P212121 
Rsym 16.5% (48.4%) 9.5% (41.8%) 
I/σ 8.4 (4.3) 11.1 (3.6) 
Completeness 95.5 % 96.7% 
Wavelength (Å) 0.9791 0.9791 
Unit cell dimensions 
a         b         c (Å) 
α        β         γ  (°) 
  
33.20   44.44   71.23   
90.0    90.0    90.0 
 
33.09    44.39    71.43  
90.0     90.0      90.0 
Refinement 
Resolution (Å) 2-35.49 2.1- 19.3 
Reflections for refinement  
(after merging Friedel Pairs) 
6690 6249 
Rfree/Rwork (%) 25.08/21.09 26.2/21.2 
Molecules in the Asymmetric 
unit 
8 8 
Solvent content (%) 54.6 54.6 
Matthews coefficient 2.71 2.71 
Total water molecules 34 52 
Total iodide atoms 0 2 
Glycerol molecule 0 1 
Rmsd bond length (Å) 0.010 0.010 
Rmsd angles (°) 1.022 0.88 
Ramachandran plot 
Allowed 
Generous 
Disallowed 
 
100 
0 
0 
 
100 
0 
0 
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Table S2. Comparison of buried surface area (BSA) and shape complementarity (Sc) of 
corkscrew with cylindrin and steric zippers. 
 
 Corkscrew Cylindrin* Steric Zipper** 
Sc 0.79 0.74 0.68 
BSA 984  943 1034 
BSA/Residue 89 86 94 
 
* PDB ID:  3SGO 
** PDB ID: 4RIL 
 
BSA values were calculated using AREAIMOL. The area buried was calculated by 
subtracting the solvent accessible surface area of one chain of the assembly from the total 
solvent accessible surface area of an isolated chain. 
Shape complementarity was calculated for one chain of the assembly. The interface 
characterized in the shape complementarity calculation is between one chain and the 
remaining chains of the assembly.  
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Table S3. Comparison of oligomers formed by cylindrin and corkscrew by ion mobility 
mass spectrometry. Cross sections of different oligomers formed by cylindrin and 
corkscrew segments are given.  
 
Oligomer 
(n) 
Cylindrin 
(MW=1199) 
SOD1(28-38) 
(MW=1215) 
1 268(+1); 262, 273(+2) 273, 288(+2), 290, 306 (+3) 
2 440(+2), 442, 452 (+3) 443, 456 (+3) 
3 625 (+3) 631 (+3), 639 (+4) 
6 1023 (+6), 1118 (+6) 1113 (+6), 1189 (+6), 
1222 (+8) 
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Table S4. Clinical information of samples used for CSAb reactivity.  
(NK – not known, NA – not applicable) 
 Clinical 
Diagnosis 
CSAb 
(Non-
neuronal) 
CSAb 
(Neuronal) 
Patholog
ic 
diagnosis 
Br
aa
k 
NF
T 
sta
ge 
Thal 
amyloid 
phase 
TDP
-43 
FHx Age Se
x 
Race 
1 ALS 0.09 1 ALS 0 0 Yes No 46 M Caucasian 
2 ALS 0.08 0 ALS 0 0 Yes No 59 F Caucasian 
3 ALS 0.10 0.2 ALS 0 0 Yes No 48 M Caucasian 
4 ALS 0.046 0.94 ALS I 0 Yes No 58 F Caucasian 
5 ALS 0.06 1 ALS I 0 Yes No 56 F Caucasian 
6 ALS 0.05 0 ALS NK NK NK NK 36 M Not 
specified 
7 Control 0.04 0.07 Control 0 0 NA No 57 M Caucasian 
8 Control 0.09 0.50 Control 0 0 No No 67 M Caucasian 
9 Control 0.09 0.27 Control III 0 NA No 71 F Caucasian 
10 Control 0.04 0 Control III 1 NA No 72 M Caucasian 
11 Control 0 0 Control NK NK NA NA 62 F Caucasian 
12 Control 0 0 Control NK NK NA NA 69 F Not 
specified 
13 Control 0 0 Control NK NK NA NA 72 M Not 
Specified 
14 Control 0.07 0.13 Control NK NK NA NA 57 M Not 
Specified 
15 Control 0.10 0.20 Control 0 0 NA NA 92 F Not 
Specified 
16 Control 0.02 0 Control 0 0 NA NA 80 M Not 
Specified 
17 ALS 0.20 0.46 ALS, 
familial 
(SOD1 
A4V) 
I 0 No Ye
s 
55 F Caucasian 
18 ALS 0.11 0.93 ALS, 
familial 
(SOD1 
G141X) 
0 0 No Ye
s 
42 F Caucasian 
19 ALS 0.14 0.87 ALS, 
familial 
(SOD1) 
0 0 No Ye
s 
55 M Caucasian 
20 ALS 0.01 1 ALS, 
familial 
(SOD1 
A4V) 
NK NK NK NK 68 M Not 
specified 
21 ALS 0 0.06 ALS, 
familial 
(SOD1 
A4V) 
NK NK NK NK 65 F Not 
specified 
22 ALS 0.10 0.87 ALS, 
familial 
(SOD1 
A4V) 
NK NK NK NK 21 F Not 
specified 
23 ALS 0.05 0.83 ALS, 
familial 
(Chr9) 
I 0 Yes Ye
s 
58 M Caucasian 
24 ALS 0.21 0.74 ALS, 
familial 
(Chr9) 
I 0 Yes No 51 F Caucasian 
25 ALS 0.26 0.94 ALS, 
familial 
(Chr9) 
I 0 Yes No 49 F Caucasian 
26 ALS-MCI 0.09 0 ALS, 
familial 
(Chr9) 
I 0 Yes No 53 M Caucasian 
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27 ALS 0.12 1 ALS, 
familial 
(Chr9) 
II 0 Yes Ye
s 
58 F Caucasian 
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Chapter 3:  Atomic structures of oligomeric segments of SOD1 suggest molecular 
differences between toxic and non-toxic amyloid oligomers 
 
 
Abstract:  The aggregation cascade of disease-related amyloidogenic proteins involves 
multiple intermediate states and ultimately results in insoluble amyloid fibrils. The 
molecular details and biochemical properties of these intermediates have been largely 
unknown. Here, we report crystal structures of variants of a cytotoxic oligomer-forming 
segment 28-38 of the ALS-linked protein, SOD1. The crystal structures reveal three 
different architectures: corkscrew oligomeric structure, non-twisting curved sheet 
structure and a steric zipper proto-filament structure. Cytotoxicity assays suggest that 
corkscrew oligomeric assembly is cytotoxic and other structures are relatively benign. 
Our works highlights the polymorphism associated with the segment 28-38 of SOD1 and 
identifies the molecular features of toxic and non-toxic entities.  
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Abstract: The aggregation cascade of disease-related amyloidogenic proteins involves 
multiple intermediate states and ultimately results in insoluble amyloid fibrils. The 
molecular details and biochemical properties of these intermediates have been largely 
unknown. Here, we report crystal structures of variants of a cytotoxic oligomer-forming 
segment 28-38 of the ALS-linked protein, SOD1. The crystal structures reveal three 
different architectures: corkscrew oligomeric structure, non-twisting curved sheet 
structure and a steric zipper proto-filament structure. Cytotoxicity assays suggest that 
corkscrew oligomeric assembly is cytotoxic and other structures are relatively benign. 
Our works highlights the polymorphism associated with the segment 28-38 of SOD1 and 
identifies the molecular features of toxic and non-toxic entities.  
 
Introduction: 
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Amyloid aggregation is implicated in a number of neurodegenerative and systemic 
diseases. Among the variety of protein aggregates known to exist, fibrillar species are the 
most readily recognized, having characteristic amyloid-like properties including the 
cross-β X-ray diffraction pattern, binding to specific dyes and birefringence upon binding 
to Congo Red (1). The cross-β diffraction pattern suggests that amyloid fibrils are 
composed of packed β-sheets. Indeed the crystal structures of amyloid-forming short 
peptides have revealed a β-sheet architecture termed steric zipper (2, 3). Their structural 
and thermodynamic stability suggests that amyloid fibers represent the energetic end state 
of the aggregation pathway. 
 
Aggregated species that evolve prior to fiber deposition are largely uncharacterized. The 
aggregation cascade of proteins is thought to evolve slowly on a time scale of decades 
and potentially has multiple intermediate states. A detailed investigation of these 
intermediates has been challenging, as these states are transient and difficult to isolate. 
Further, multiple segments in any protein may act synergistically or independently to 
form different intermediate structures. Thus, the identification of these intermediate states 
and detailed characterization of their cytotoxic roles has been limited.  
 
Studies over the last two decades have suggested that small oligomers that form 
transiently in the aggregation pathway exacerbate disease progression by exerting toxicity 
in neuronal cells (4, 5). The failure of fiber-inhibiting therapeutics in clinical trials and 
the low cytotoxicity of amyloid fibers in various model systems suggest that small 
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oligomers may be the toxic intermediate state in amyloid diseases. It is accepted that 
amyloid oligomers are β-sheet rich, cytotoxic and bind conformational antibodies such as 
A11. Structural studies have revealed anti-parallel, β-sheet rich oligomeric structures of 
proteins such as amyloid-β, α-B crystallin and SOD1 (6, 7). Although it is appreciated 
that the aggregation of these proteins has multiple intermediates, the molecular details 
and biochemical properties of these intermediates are largely unknown.  
 
ALS is a fatal neurodegenerative disease caused by degeneration of motor neurons that 
results in loss of muscle control and paralysis. SOD1, a ubiquitously expressing cytosolic 
protein is found in insoluble aggregates in a subset of familial ALS patients. An 
exceptionally stable protein, the aggregation of SOD1 has been attributed to structural 
perturbations induced by the familial mutations or oxidative damage accumulated over 
time (8, 9). Recently we discovered that SOD1 forms cytotoxic soluble oligomers with 
the segment 28-38 of SOD1 as the oligomeric core. The segment is cytotoxic to cultured 
motor neurons and substitutions at Gly33 with bulky residues alleviate toxicity by 
disrupting oligomer formation. Here we report three new crystal structures of different 
variants of this segment that reveal possible aggregation intermediates. Biochemical 
characterization of these aggregation states helps differentiate the molecular features of 
toxic and non-toxic structures.  
 
Results:  
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1. Segment 28-38 of SOD1 has a high aggregation propensity – One of the critical 
questions raised by the discovery of corkscrew (Sangwan et al.) is whether it is the only 
toxic conformation or if the segment forms more than one toxic intermediate state. 
Additionally, the presence of familial mutations in the segment led us to investigate the 
effect of these mutations. Notably, the segment has a low frequency of familial mutations 
and only three amino acid substitutions (Ala, Arg and Val) have been found so far. 
Among the various familial mutations found in this segment: Ala substitutes for V29 and 
V31 and Arg and Val substitutes for G37 and L38. We hypothesized that G37R would 
have a potentially large effect on the aggregation kinetics of this segment due to the 
change from a small amino acid to a charged amino acid (Fig. 1A, left). G37R has been 
previously characterized extensively and shown to increase the aggregation propensity of 
the full-length protein leading to rapid disease onset and progression in transgenic mice 
models (10). We also analyzed the fiber-forming propensity of the segment using 
ZipperDB (11), an algorithm that predicts the propensity of six residue segments to form 
amyloid fibrils (Fig. 1A, right). ZipperDB showed two aggregation-prone subsegments - 
31-KVWGSI-36 and 33-GSIKGL-38. Thus, we set out to characterize the G37R mutant 
as well as the shorter 6-residue subsegments. 
 
2. Crystal structure of segment 28-38 with familial mutation G37R reveals a different 
corkscrew geometry – We obtained crystals of the segment 28-38 harboring the familial 
mutation G37R (i.e. the tenth residue in the sequence KVKVWGSIKRL). The peptide 
used in crystallization trials has an additional residue change of P28K used to increase 
solubility of the segment. This substitution has been shown previously to contribute 
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minimally to the structure and cytotoxic properties. The structure was solved by 
molecular replacement using the native corkscrew as a search model (sequence 
KVKVWGSIKGL, PDB ID 5DLI). The structure reveals a twisted b-sheet with the same 
antiparallel, out-of-register β-strand construction as the wild type corkscrew (Fig. 1B); 
however G37R has more strands per turn (20 vs. 16), a shorter pitch length (59 Å vs. 71 
Å) and larger diameter (38 Å vs. 25 Å). This difference is supported by Arg37, which 
engages in multiple inter- and intra-strand interactions. The charged side chain of Arg37 
forms hydrogen bonds with the C-terminal carboxylate (Leu38) of alternate strands or of 
the same strand (Fig. 1C). These interactions are not possible with native Gly residue and 
support the shorter pitch length. The overall similarity of the mutant structure to the 
corkscrew suggests that the segment has a high propensity to form antiparallel, out-of-
register assemblies although single point substitutions can induce subtle changes in the 
overall architecture. 
 
3. Orange G supports untwisting of the corkscrew segment 28-38 with familial 
mutation G37R– In our efforts to obtain phases for the mutant segment; we crystallized 
a derivative with a bromo-allyl valine at position 2 (sequence KBKVWGSIKRL). We 
obtained crystals in the presence of orange G, a small aromatic dye previously shown to 
modulate amyloid formation of Alzheimer’s disease-associated proteins, amyloid-β and 
tau (12). The crystals displayed a needle-like morphology distinctly different from the 
crystals of the mutant peptide KVKVWGSIKRL. The crystals diffracted to 1.8 Å and 
phases were obtained by molecular replacement using the corkscrew structure as a search 
model. The structure revealed a curved b-sheet with the same antiparallel, out-of-register 
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β-sheet construction as the wild type and G37R corkscrews, but surprisingly no twist 
(Fig. 2A).  
 
As with both corkscrews, the curvature of the sheet is stabilized by short hydrophobic 
side chains (valine and isoleucine) pointing into the concave interior and charged and 
bulky residues pointing outward from the convex exterior; however, all twist is 
eliminated apparently due to orange G-mediated contacts between neighboring sheets. 
Stacked aromatic side chains of W32 intercalate with the aromatic rings of orange G (Fig. 
2B). The aromatic rings of orange G stack against the Trp32 aromatic side chains and the 
sulfate moieties of orange G form salt bridges with K30 of both sheets (Fig. 2C, 2D). 
Together, these interactions result in a high binding energy (-12.4 kcal/mol) and 
favorable shape complementarity (0.82). Previously, orange G had been observed bound 
to a steric zipper composed of a 6-residue segment of amyloid-β. The aromatic rings of 
orange G stacked with similar aromatic stacking and salt bridges but in a slightly altered 
conformation (13).  
 
4. Crystal structure of the segment 30-KVWGSI-35 reveals a steric zipper – We also 
obtained diffraction quality crystals of the  subsegment, 30-KVWGSI-35. The 6-residue 
segment forms a steric zipper composed of in-register, anti-parallel β-sheets that are 
arranged face-to-back. It is a Class 7 zipper (3). Notably, the side chains of neighboring 
sheets do not pack as tightly as most pathogenic steric zippers, apparently due to the 
conflicting sizes and properties of the side chains in the interface (shape complementarity 
=0.65); a void between sheets is filled adventitiously by a trifluoroacetic acid molecule. 
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The side chain of W32 extends along the zipper axis and stacks against the backbone of 
G33 of the strand above it in the sheet (Fig. 3B) and results in staggering of the sheets 
relative to each other (Fig. 3C). 
 
5. Variant peptides show distinct diffraction patterns – We performed fiber diffraction 
on the native corkscrew forming peptide (KVKVWGSIKGL, PDB ID 5DLI) as well as 
the familial mutant crystallized here (KVKVWGSIKRL and KBKVWGSIKRL). 28-38 
and G37R mutant peptides produce a distinct diffraction ring at 4.6 Å (Fig. 4E). The 
absence of reflections at 10 Å indicates a β-sheet rich structure that is devoid of pairs of 
sheets. Interestingly, the segment forming untwisted structure (KBKVWGSIKRL) gives 
a distinct diffraction pattern with multiple rings notably at 4.75 Å and 9.5 Å. We also 
collected the diffraction patterns after fibrillization and found that the native 28-38 
segment shows rings at 4.6 Å and 11.9. The segment KBKVWGSIKRL shows diffraction 
at 4.75 Å, 9.5 Å and 13.1 indicative of a mixture of different β-sheet structures. Together, 
these data suggest that the corkscrew assembly is the predominant oligomeric 
intermediate state. 
 
6. Orange G favors untwisting of the corkscrew and alleviates toxicity of the segment – 
We investigated the cytotoxic properties of G37R 28-38 segment (KVKVWGSIKRL) in 
different aggregation states. For these experiments, we incubated the segment at 37° both 
under quiescent conditions to promote oligomer assembly and shaking conditions to 
promote fibril assembly.  We then assessed the cytotoxic properties of both preparations 
on cultured cells. Although the segment was cytotoxic in both conditions, we observed 
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higher cytotoxicity in oligomer-promoting quiescent conditions (Fig. 5A). Transmission 
electron microscopy (TEM) verified that samples prepared under quiescent conditions 
contained no fibrils whereas those prepared by agitation showed fibrils (Fig. 5B). 
Additionally, we utilized the propensity of the curved sheet architecture to bind orange G. 
We hypothesized that under oligomer-forming conditions, the addition of orange G 
would drive the equilibrium towards the non-twisting sheet architecture and thus rescue 
toxicity. We incubated the mutant peptide (KVKVWGSIKRL) with orange G under 
oligomer-promoting conditions and assessed cytotoxicity thereafter.  Given that orange G 
is a known modulator of fibril formation, we only added sub-stoichiometric amounts to 
induce subtle changes in populating corkscrew or untwisted conformations. We observed 
a small but significant rescue of toxicity (Fig. 5E). As a control, we used 8-
hydroxypyrene 1,3,6 – trisulfonic acid, a small molecule dye that we predicted would not 
affect the aggregation kinetics as it has low affinity for all types of amyloid architectures 
as calculated by computational calculations (Fig. 5C, 5D). Co-incubation with 8-
hydroxypyrene 1,3,6 trisulfonic acid did not affect the cytotoxic properties suggesting 
that orange G was specifically rescuing toxicity by promoting untwisting of the β-sheet. 
Taken together, these data suggest that out-of-register twisted sheets are cytotoxic while 
untwisted sheets are relatively non-toxic. 
 
Discussion: 
 
Building on our discovery of segment 28-38 as the toxic oligomeric core of SOD1, here 
we characterize the segment by determining three atomic structures of its variants and 
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characterizing their biochemical properties. The three structures we determined possibly 
reveal three different aggregation states: corkscrew, a soluble oligomer, the untwisted 
sheet, an out of register intermediate structure and steric zipper representing the fibrillar 
state. 
 
The crystal structure of the G37R mutant segment suggests that the mutation stabilizes 
the corkscrew oligomer assembly. More than 180 different ALS-linked familial mutations 
are known in the 153-residue dimeric protein, SOD1. Among those found in segment 28-
38, G37R was one of the first familial mutations found in familial ALS patients (14). In 
transgenic mouse models, overexpression of the G37R mutant protein leads to rapid 
disease onset and progression (10) and in cell culture models it has been shown to 
increase oligomer formation and toxicity (15). The atomic structure of the 28-38 segment 
with the mutation G37R forms a corkscrew assembly composed of anti-parallel out-of-
register β-strands. The change from a small glycine residue to a large arginine residue 
forms several hydrogen bonds stabilizing the corkscrew assembly. This stabilization of 
the corkscrew oligomers could explain the increased toxicity of the G37R mutant protein. 
 
Our structures of wild type and G37R mutant SOD1 segment 28-38 suggest that the 
corkscrew architecture is robust and may accommodate a range of other sequences with 
the same pattern. That is, small hydrophobic residues alternating with bulky or like-
charged residues, forming the concave and convex surfaces of the corkscrew, 
respectively. Hence, the corkscrew architecture may be implied in pathology of other 
neurological amyloid diseases. 
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We obtained the atomic structure of the G37R variant peptide, KBKVWGSIKRL in a 
novel conformation. Instead of extended β-sheet conformation seen in steric zippers and 
corkscrew, here the strands are curved forming a dry interface on both faces of the 
strands. This structure belongs to the growing class of out-of-register steric zippers (16). 
KDWSFY a short segment of β2-microglobulin and NFGAILS a short segment of IAPP 
were previously reported to form out-of-register sheet structures (17, 18). An out-of-
register sheet structure of a 11-residue segment of IAPP was recently determined (19). 
Notably, the IAPP structure was composed of a single sheet and was also found to be 
non-toxic. The 11-residue structure reported here is composed of pairs of sheets and is the 
longest segment crystallized in an out-of-register mating sheet conformation. Similar to 
the structure of KDWSFY, the mating sheets of the zipper are not parallel to each other 
but form a crossing angle of ~45°. 
 
Diffraction of the native corkscrew forming segment KVKVWGSIKGL as well as the 
G37R mutant KVKVWGSIKRL showed similar diffraction patterns with a diffuse ring at 
4.6 Å. The absence of reflections at 10 Å suggests a single sheet architecture of the 
oligomer different from the classical amyloid cross-β diffraction that shows reflections at 
4.8 Å and 10.4 Å.  Indeed under shaking conditions the diffraction pattern of 
KVKVWGSIKGL showed diffraction at 4.6 Å and 11.9 Å.  
 
We determined the crystal structure of the variant peptide, KBKVWGISKRL in an out-
of-register untwisted conformation. Orange G that was used as an additive was found to 
 123 
bind in the interface between the two sheets. Docking simulations also suggested that 
orange G has a high propensity to bind the interface compared to the twisted corkscrew 
structure. Based on these results, we hypothesized that binding of orange G stabilizes the 
untwisted structure and drives the equilibrium from cytotoxic corkscrew oligomers to the 
untwisted structure. Indeed, in cytotoxicity assays we observed a partial rescue of 
cytotoxicity upon addition of orange G. Although we cannot rule out if orange G 
stabilizes other non-toxic intermediates, our results suggest that small molecules designed 
to stabilize untwisted structure can alleviate cytotoxicity of aggregated proteins.  
 
In summary, our structural studies of the SOD1 segment suggest that twisted sheets are 
cytotoxic whereas steric zipper and non-twisted sheets are relatively non-toxic. 
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Figure Legends 
Fig. 1. Crystal structure of SOD1 segment harboring a familial mutation, G37R. (A) 
(Left) Frequency of ALS-associated mutations in SOD-1 residues 28-38. (Right) 
Estimated energies of steric zippers formed by six-residue segments within segment 28-
38. Segments KVWGSI and GSIKGL have energies of −23 kcal/mol or lower and are 
predicted to form fibrils. (B) 2.9 Å crystal structure of the toxic oligomeric core of SOD1, 
residues 28-38 with the familial mutation G37R reveals a corkscrew assembly of anti-
parallel β-strands with a hydrophobic cleft composed of valine and isoleucine residues. 
20 strands form one complete turn with a pitch length of 59 Å and diameter of 38 Å. (C) 
Arg37 forms multiple inter- and intra-chain interactions that increase the stability of the 
assembly. (Top) Shown here Arg37 of β7 forms an intra-chain hydrogen bond with 
Leu38 and an inter-chain hydrogen bond with Leu38 of β9. (Bottom) Arg37 also forms 
inter-chain hydrogen bonds. Shown here Arg37 of β14 is engaged in hydrogen bonds 
with Leu38 of β12 and Arg37 of β16. 
 
Fig. 2. Polymorphic form of the segment 28-38 with the familial mutation G37R. (A) 
Atomic structure of the segment 28-38 with familial mutation G37R at 1.8 Å resolution 
reveals a novel architecture of highly curved sheets mating via stacking of aromatic side 
chains of W32 residue. The curved architecture enables both faces of the sheets to 
exclude water molecules as shown here in side and top views. (B) The weak interface 
composed of W32 stacking forms a pocket where small molecules can bind. Orange G 
(shown in orange sticks) was co-crystallized and found to bind in the pocket. (C) Electron 
density map contoured at 1.0 σ showing clear density for orange G. (D) Orange G 
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stabilizes the assembly by forming a network of hydrogen bonds with K30 and W32 of 
one sheet and K30 of the opposing sheet. Water molecules are colored red.   
 
Fig. 3. Segment 30-KVWGSI-35 of SOD1 forms a steric zipper assembly. (A) 1.45 Å 
resolution structure of segment KVWGSI shows two β-sheets composed of anti-parallel 
β-strands forming a class 7 steric zipper via face to back stacking. Shown here in top 
(left) and side (right) views. Trifluoroacetic acid (TFA) is colored orange. (B) The two 
sheets do not pack tightly due to the bulky tryptophan side chain in the inner interface, 
(C) Instead of a flat parallel packing, the W32 side chain protrudes along the fiber axis 
and aligns with the G33 of strand above it as shown here in sphere representation, which 
causes staggering of the sheets relative to each other. 
 
Fig. 4. Structural comparison of segment 28-38 and its variants. (A) The native 28-38 
segment (PDB ID: 5DLI) forms a corkscrew-like assembly of anti-parallel, out-of-
register β-strands. 16 strands form one complete turn with 71 Å pitch length and 25 Å 
diameter. (B) The mutant segment with a familial mutation, G37R forms a corkscrew-like 
assembly but with a different pitch length and diameter. 20 strands form one complete 
turn with 59 Å pitch length and 38 Å diameter. (C) A second form of the variant segment 
was obtained which revealed a novel architecture of curved out-of register sheets. The 
sheets are not exactly perpendicular to fibril axis and instead are tilted with a crossing 
angle of ~45°. (D) A shorter 6-residue segment within 28-38 forms a steric zipper 
composed of pairs of β-sheets. The sheets are perpendicular to the fibril axis with a 0° 
crossing angle. (E) Comparison of diffraction patterns of the different variant segments. 
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(Top) 28-38 and G37R mutant segments show diffuse diffraction rings at 4.6 Å. The 
G37R segment forming out-of-register pairs of sheets forms sharp diffraction rings at 
4.75 Å and 9.5 Å. (Bottom) The segment 28-38 and the sheet forming structures under 
shaking conditions reveal cross-β diffraction indicative of pairs of sheets.  
 
Fig. 5. Familial mutant segment is cytotoxic and addition of orange G partially 
alleviates the cytotoxicity. (A) Segment KVKVWGSIKRL was aggregated under 
quiescent and shaking conditions at different concentrations and its cytotoxicity was 
assessed thereafter. Under oligomer-forming, quiescent conditions the segment was more 
cytotoxic. (B) Electron micrographs of the segment under different conditions. Some 
fibrils can be seen in shaking conditions but not under quiescent conditions suggesting 
that cytotoxicity is a property of soluble corkscrew-like oligomers. (C,D) Docking 
simulations of the different structures determined here and the small molecule dye orange 
G. Binding Energy is reported in Rossetta Energy Units (REU). Notice that orange G has 
lower binding energy to form 2 than wild type. A small molecule 8-hydroxypyrene 1,3,6 
– trisulfonic acid was used as a negative control and had high binding energies to wild 
type corkscrew as well as untwisted structure. (E) Cytotoxicity of 800 µM segment when 
aggregated in the presence of 100 µM orange G or a non-binding control molecule. 
Addition of orange G alleviates the cytotoxic effects suggesting that the untwisted curved 
sheet architecture is relatively benign. Results shown as Mean+SD. Statistical 
significance was analyzed by one-way ANOVA (ns not significant, ** p < .01, **** p < 
.0001) 
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Table 1: Data collection and refinement statistics 
 KVKVWGSIKRL 
(Form 1) 
KBrKVWGSIKRL 
(Form 2) 
KVWGSI 
Beam line APS 24-ID-E APS 24-ID-E APS 24-ID-E 
Resolution Å 2.9 1.80 1.45 
Total unique 
reflections  
5444 2330 1738 
Total reflections 
observed 
27350 7194 11632 
Space group P3121 C2 P212121 
Rsym 18.3% (90.7%) 21.1%(197.9%) 16.6 %(55.0%) 
I/σ 8.9 (1.0) 4.06(0.48) 8.6(1.6) 
Completeness 98.9 % 96.6 89.6 
Wavelength (Å) 0.9791 0.9791 0.9791 
Unit cell dimensions 
a         b         c (Å) 
α        β         γ  (°) 
 
59.61 59.61 98.92 
90.0 90.0 120.0 
 
56.94 11.64 44.93 
90.0 127.3 90.0 
 
9.51 20.28 44.24 
90.0 90.0 90.0 
Refinement 
Resolution (Å) 2.8 - 45.8 1.8 - 35.7 1.4 - 22.1 
Reflections for 
refinement  
5422 2327 1564 
Rfree/Rwork (%) 25.04/21.32 26.70/23.03 16.97/17.06 
Molecules in the 
Asymmetric unit 
10 2 2 
Solvent content (%) 71 50 24 
Matthews 
coefficient 
4.19 2.45 1.61 
Total water 
molecules 
14 16 6 
Glycerol molecule 1 0 0 
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Malonate molecule 3 0 0 
TFA molecule 0 0 1 
Orange G 0 1 0 
Rmsd bond length 
(Å) 
0.010 0.010 0.020 
Rmsd angles (°) 1.18 1.25 2.00 
Ramachandran plot 
Allowed 
Generous 
Disallowed 
 
96 
4.44 
0 
 
94 
5.56 
0 
 
100 
0 
0 
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Table 2: Comparison of shape complementarity (Sc) and buried surface area (Ab) of 
oligomers of SOD1 segments. 
 
 KVKVWGSIKRL 
Form 1 
KVKVWGSIKRL 
Form 2 
KVWGSI 
Sc 0.76 0.76 0.64 
Ab (Å2) 1195 1047 621 
Ab/Residue (Å2) 109 95 104 
 
 
For the Sc calculation, we examined the interface between one chain and the remaining 
chains of the assembly. 
Ab values were calculated using AREAIMOL. The area buried was calculated by 
subtracting the solvent accessible surface area of one chain of the assembly from the total 
solvent accessible surface area of an isolated chain. Notice that the N-terminal prolyl 
residue of these SOD1 segments has been replaced by lysyl to improve solubility. 
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Materials and Methods: 
 
Crystallization: All peptides were commercially obtained from Genscript inc. with more 
than 98% purity. All data were collected at the Advanced Photon Source (Chicago, IL) on 
beamline 24-ID-E and data were processed using DENZO and SCALEPACK or XDS 
(20). Structures were built using COOT (21). Model refinement was performed using 
REFMAC (22) and BUSTER (23). Figures were generated using PyMOL (24).  
 
28-KVKVWGSIKRL38: Crystals of segment 28-38 with P28K and G37R 
substitution were grown by hanging drop vapor diffusion using VDX plates (Hampton 
Research, Aliso, Viejo, CA). Lyophilized peptide was dissolved to 50 mg/ml in 50 
mM Tris-base buffer, 1 mM Orange G. The reservoir solution contained 0.3 M sodium 
malonate and 15% PEG 3350. Crystallization drops were prepared by mixing peptide 
with reservoir in a 3:1 ratio, in a total volume of 4 µL. The crystals were subsequently 
flash frozen in liquid nitrogen and mounted with CrystalCap HT Cryoloops (Hampton 
Research, Aliso Viejo, CA). Four strands composed of the core of the corkscrew 
structure PDB ID: 5DLI, residues VKVWGSI were used as the initial model for 
molecular replacement.  
 
28-KBKVWGSIKRL-38: Lyophilized peptide (KBKVWGSIKRL, B represents the 
non-natural amino acid bromo-allyl valine)  was dissolved to 50 mg/ml in 50 mM 
Tris-base buffer with 1 mM Orange G. The reservoir solution contained 0.1 M HEPES 
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pH 7.5, 0.2 M sodium citrate and 15% MPD. Needle-like crystals appeared overnight 
and were directly flash frozen from the original screening plate.  
 
30-KVWGSI-35: Lyophilized peptide was dissolved to 50 mg/ml in water and filtered 
by 0.1 µm filter. Crystals were grown by hanging drop vapor diffusion using VDX 
plates (Hampton Research, Aliso, Viejo, CA). Crystallization drops were prepared by 
mixing peptide with reservoir in a 2:1 ratio, in a total volume of 3 µL. The reservoir 
solution contained 4 M Sodium Formate. Crystals were mounted on pulled glass 
capillaries without any cryoprotectant. A pair of anti-parallel β-strands was used as an 
initial model for molecular replacement. 
 
Fiber Diffraction: Peptide segments were dissolved in 50 mM tris-base buffer at 25 
mg/ml and incubated at 37 °C without agitation to form oligomers for four days. For 
fibril preparations, the peptide segments were incubated at 37 °C in Torry Pine shakers 
for four days. 
 
Segment Aggregation: Peptide segments were aggregated by incubation at 37 °C for 12 
hours with agitation in 50 mM tris-base buffer and added to cultured neurons. For testing 
the effect of small molecules, peptides were co-incubated with Orange G (Sigma Aldrich, 
Cat # 861286) and 8 hydroxypyrene 1,3,6 – trisulfonic acid (Sigma Aldrich, Cat # 1529) 
at 37 °C overnight without agitation and added to cultured cells at a final concentration of 
800 µM peptide and 100 µM small molecule.  
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Ligand Docking: Three dimensional structures of the ligands used for docking 
simulation were downloaded from the PubChem Compound Database (CID=24181578, 
4254851)(25). We generated the ligand perturbation ensemble using the method 
described previously (26). A torsion angle deviation of ±5° for each rotatable bond of the 
ligand was applied to generate 100 conformations for each ligand. Ligand docking was 
performed using the HighResDocker protocol in Rosetta version 3.5, using the 
talaris2014 energy function (27). Docking poses were sampled in a 7 Å box centered at 
the known binding site of Orange G to the variant form 1, or to the corresponding 
residues in the corkscrew structure. Small ligand perturbations were coupled with cycles 
of side chain repacking, in which rotamers of side chains around the ligand are optimized 
in a Monte-Carlo minimization algorithm. Ligand poses were ranked based on lowest 
binding energy. 
 
Cell Culture:  Rat Neuroblastoma (PC12) cells were obtained from ATCC (CRL 1721). 
Cells were cultured in RPMI 1640 media with 10% heat inactivated horse serum and 5% 
fetal bovine serum. 
 
Cytotoxicity Assays 
Cells were plated at 10,000 cells per well in 96-well tissue culture plates and allowed to 
adhere overnight before treatment with aggregated peptides. Upon treatment with the 
aggregated peptides, cells were incubated overnight and cell viability was measured using 
the commercially available MTT assay (Promega Cat#G4100) according to the 
manufacturer’s protocol with 4 hour incubation with the MTT reagent. All data were 
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normalized using buffer as 100% viability and 0.2% SDS as 0% viability. Experiments 
were performed in triplicates. 
 
Electron Microscopy 
Each 3-5 µL sample was spotted directly on freshly glow-discharged carbon-coated 
electron microscopy grids (Ted Pella, Redding, CA). After 4 min incubation, grids were 
rinsed twice with 5 µL distilled water and stained with 5 µl of 2% uranyl acetate for 1 
min. Excess uranyl acetate was removed by blotting and specimens were examined on a 
T-12 electron microscope at an accelerating voltage of 80 kV. Images were recorded 
digitally by wide angle (top mount) BioScan 600W 1 × 1K digital camera (Gatan, 
Pleasanton, CA). 
 
 
  
 140 
References: 
 
1.  Eisenberg D, Jucker M (2012) The Amyloid State of Proteins in Human Diseases. 
Cell 148(6):1188–1203. 
2.  Nelson R, et al. (2005) Structure of the cross-β spine of amyloid-like fibrils. Nature 
435(7043):773–778. 
3.  Sawaya MR, et al. (2007) Atomic structures of amyloid cross-β spines reveal varied 
steric zippers. Nature 447(7143):453–457. 
4.  Bernstein SL, et al. (2009) Amyloid-β protein oligomerization and the importance of 
tetramers and dodecamers in the aetiology of Alzheimer’s disease. Nat Chem 
1(4):326–331. 
5.  Celej MS, et al. (2012) Toxic prefibrillar α-synuclein amyloid oligomers adopt a 
distinctive antiparallel β-sheet structure. Biochem J 443(3):719–726. 
6.  Laganowsky A, et al. (2012) Atomic View of a Toxic Amyloid Small Oligomer. 
Science 335(6073):1228–1231. 
7.  Liu C, et al. (2011) Characteristics of Amyloid-Related Oligomers Revealed by 
Crystal Structures of Macrocyclic β-Sheet Mimics. J Am Chem Soc 133(17):6736–
6744.  
 141 
8.  Guareschi S, et al. (2012) An over-oxidized form of superoxide dismutase found in 
sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism 
with mutant SOD1. Proc Natl Acad Sci 109(13):5074–5079. 
9.  Valentine JS, Hart PJ (2003) Misfolded CuZnSOD and amyotrophic lateral sclerosis. 
Proc Natl Acad Sci 100(7):3617–3622. 
10.  Wong PC, et al. (1995) An adverse property of a familial ALS-linked SOD1 mutation 
causes motor neuron disease characterized by vacuolar degeneration of 
mitochondria. Neuron 14(6):1105–1116. 
11.  Goldschmidt L, Teng PK, Riek R, Eisenberg D (2010) Identifying the amylome, 
proteins capable of forming amyloid-like fibrils. Proc Natl Acad Sci 107(8):3487–
3492. 
12.  Necula M, Kayed R, Milton S, Glabe CG (2007) Small Molecule Inhibitors of 
Aggregation Indicate That Amyloid beta Oligomerization and Fibrillization 
Pathways Are Independent and Distinct. J Biol Chem 282(14):10311–10324. 
13.  Landau M, et al. (2011) Towards a Pharmacophore for Amyloid. PLoS Biol 
9(6):e1001080. 
14.  Rosen DR, et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are 
associated with familial amyotrophic lateral sclerosis. Nature 362(6415):59–62. 
 142 
15.  McAlary L, Aquilina JA, Yerbury JJ (2016) Susceptibility of Mutant SOD1 to Form 
a Destabilized Monomer Predicts Cellular Aggregation and Toxicity but Not In 
vitro Aggregation Propensity. Front Neurosci 10. doi:10.3389/fnins.2016.00499. 
16.  Eisenberg DS, Sawaya MR (2017) Structural Studies of Amyloid Proteins at the 
Molecular Level. Annu Rev Biochem 86(1). doi:10.1146/annurev-biochem-061516-
045104. 
17.  Liu C, et al. (2012) Out-of-register β-sheets suggest a pathway to toxic amyloid 
aggregates. Proc Natl Acad Sci 109(51):20913–20918. 
18.  Soriaga AB, Sangwan S, Macdonald R, Sawaya MR, Eisenberg D (2016) Crystal 
Structures of IAPP Amyloidogenic Segments Reveal a Novel Packing Motif of Out-
of-Register Beta Sheets. J Phys Chem B 120(26):5810–5816. 
19.  Krotee P, et al. (2017) Atomic structures of fibrillar segments of hIAPP suggest 
tightly mated β-sheets are important for cytotoxicity. eLife 6. 
doi:10.7554/eLife.19273. 
20.  Kabsch W (1993) Automatic processing of rotation diffraction data from crystals of 
initially unknown symmetry and cell constants. J Appl Crystallogr 26(6):795–800. 
21.  Emsley P, Cowtan K (2004) Coot : model-building tools for molecular graphics. Acta 
Crystallogr D Biol Crystallogr 60(12):2126–2132.  
 143 
22.  Vagin AA, et al. (2004) REFMAC 5 dictionary: organization of prior chemical 
knowledge and guidelines for its use. Acta Crystallogr D Biol Crystallogr 
60(12):2184–2195. 
23.  Bricogne G, et al. BUSTER version 1.10.0. Cambridge, United Kingdom: Global 
Phasing Ltd. 
24.  Delano W The PyMOL Molecular Graphics System. (2002). 
25.  National Center for Biotechnology Information. PubChem BioAssay Database. 
26.  Jiang L (13AD) Structure-based discovery of fiber-binding compounds that reduce 
the cytotoxicity of amyloid beta. eLife 2013;2:e00857. 
27.  Lemmon G, Meiler J (2012) Rosetta Ligand Docking with Flexible XML Protocols. 
Computational Drug Discovery and Design, ed Baron R (Springer New York, New 
York, NY), pp 143–155. 
  
 144 
Chapter 4: Inhibition of synucleinopathic seeding by structure-based designed inhibitors  
 
Abstract: Seeding, in the context of amyloid disease, is the sequential transfer of 
pathologic protein aggregates along connected tissues. This process contributes to 
progression and severity of neurodegenerative diseases. To date, there are no therapeutics 
that specifically target seeding, in part, due to lack of information of the structural 
properties of pathological seeds. Here we use a rational approach based on the atomic 
structure of the core of PD-related α-synuclein fibrils, to design small peptidic inhibitors. 
The inhibitors prevent aggregation of α-synuclein in vitro and in cell culture models. The 
inhibitors also show efficacy in preventing seeding by patient-derived α-synuclein fibrils 
both in vitro and in cell culture models. Our results suggest that pathological seeds of α-
syn contain steric zippers and suggest a therapeutic approach targeted at the spread and 
progression that may be applicable for PD and related synucleinopathies.  
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Abstract:  
 
Seeding, in the context of amyloid disease, is the sequential transfer of pathologic protein 
aggregates along connected tissues. This process contributes to progression and severity 
of neurodegenerative diseases. To date, there are no therapeutics that specifically target 
seeding, in part, due to lack of information of the structural properties of pathological 
seeds. Here we use a rational approach based on the atomic structure of the core of PD-
related α-synuclein fibrils, to design small peptidic inhibitors. The inhibitors prevent 
aggregation of α-synuclein in vitro and in cell culture models. The inhibitors also show 
efficacy in preventing seeding by patient-derived α-synuclein fibrils both in vitro and in 
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cell culture models. Our results suggest that pathological seeds of α-syn contain steric 
zippers and suggest a therapeutic approach targeted at the spread and progression that 
may be applicable for PD and related synucleinopathies. 
  
Introduction:  
 
Parkinson’s disease (PD), dementia with lewy bodies (DLB) and multiple system atrophy 
(MSA) are together classified as Synucleinopathies, a class of neurodegenerative diseases 
characterized by the pathological accumulation of the protein, α-synuclein (α-syn) in 
neuronal cells (1). Together these make up the second most common form of 
neurodegenerative disease. α-synuclein, a 140 amino acid protein is found in amyloid 
deposits in neuronal cells in disease conditions. A causative link between α-syn amyloid 
formation and disease progression is supported by the findings that gene duplications and 
familial mutations that increase amyloid load also cause early-onset PD, and more than 
90% sporadic PD patients stain positive for α-syn deposits.  
 
Based on structural studies, a number of different models for α-syn fibrils have been 
proposed. Limited proteolysis and NMR studies suggest that the fibril core is composed 
of residues 30-100 (2). Crystal structures and NMR studies suggest different models of α-
syn fibrils. In one model based on crystal structures of short segments, two monomers per 
sheet form extended steric zippers (3). In a second ssNMR-based model, a greek key 
topology with one monomer per sheet has been shown (4). Taken together these studies 
suggest that α-syn can form polymorphic fibrillar architectures. 
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The segment 68-78 of α-syn termed NACore forms the core of α-syn fibrils.  NACore, 
resides within the 35-residue NAC (non-amyloid β component) domain found in amyloid 
deposits (3). NACore aggregates readily, and the aggregates display properties such as 
diffraction pattern and cytotoxicity similar to full-length α-syn. Additionally, β-synuclein, 
a homologue does not contain residues 74-84 and is not found in amyloid deposits, and 
removal of residues 71-82 has been shown previously to reduce the aggregation and 
toxicity in vitro and in a drosophila model (5, 6). Additionally, a modification at Thr72 
prevents its aggregation propensity 
 
Apart from the spontaneous aggregation of intracellular α-syn into amyloid fibrils, a 
second phenomenon that contributes to disease progression is the prion-like spread of α-
syn aggregates (7). Braak staging has shown that pathology gradually spreads over time 
through connected brain regions, and cell culture and animal models show that small 
amounts of α-syn aggregates can act as seeds and induce aggregation of the native protein 
(8–12). Although distinct from canonical prions that can be transmitted from person to 
person, this phenomenon of ‘seeding’ seems the driver of disease progression. 
 
Although α-syn amyloid formation has been extensively characterized, little headway has 
been made in developing therapeutics that can prevent spontaneous α-syn aggregation or 
reduce the prion-like spread. Among promising approaches are antibodies that sequester 
α-syn aggregates and small molecule stabilizers that bind α-syn monomers (13, 14). Here 
we report a third class of inhibitors that bind α-syn seeds and prevent their growth and 
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elongation. The inhibitors are designed using the atomic structure of NACore as a 
template. We show the efficacy of these inhibitors in preventing fibril formation and 
seeding in vitro and in cell-based seeding model systems. 
 
Results:  
 
1. Rational design of α-synuclein aggregation inhibitors: We utilized the atomic 
structure of NACore [68-GAVVTGVTAVA-78] as a template and using computational 
and structure-based approaches designed peptidic inhibitors. The atomic structure of 
NACore revealed a pair of self-complementary β-sheets forming a steric zipper (15). The 
inhibitors are predicted by Rossetta-based computational modeling to bind the steric 
zipper interface and ‘cap’ the fibrils. We identified 3 candidates, S37, S61 and S71 that 
bind favorably with one or both ends of the zipper (Fig. 1). The binding energies and 
shape complementarity of the three inhibitors are also favorable (Fig 1B).  All the 
inhibitors retain most residues of the native sequence of NACore but contain one or more 
modified residues. Rodriquez et al. showed that a smaller 9-residue segment within 
NACore [69-AVVTGVTAV-77] aggregates slower than NACore and the structure is 
similar to NACore. In order to prevent the self-aggregation of our designed inhibitors, we 
used the shorter segment along with one or more modifications. S37 has a W mutation at 
Thr72 and an additional poly-lysine tag at the C-terminus to induce charge-charge 
repulsion. It is predicted to bind both tips of the steric zipper fibril. S61 and S62 retain 
the same inhibitor sequence as S37 but instead of poly-lysine tag, a TAT tag is added to 
aid solubility and prevent self-aggregation. S71 has a methylated glycine at Gly73 that 
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weakens hydrogen bonding along the β-sheet and an additional TAT tag for solubility 
and cell penetration.  
 
2. Designed inhibitors prevent aggregation in vitro: We tested the efficacy of the 
inhibitors in an in vitro aggregation assay. Recombinantly purified α-syn was aggregated 
in the presence of the inhibitors and monitored by measuring fluorescence of Thioflavin 
T, an amyloid binding dye. All three inhibitors prevented aggregation with a significant 
reduction in ThT fluorescence (Fig. 1C, 1D, 1E).  
 
3. α-syn aggregates formed in the presence of inhibitors show reduced seeding 
in cell culture models: We tested the efficacy of the inhibitors in preventing aggregation 
in a cell culture model. For these assays, we utilized two HEK293T cells that stably 
express YFP-labeled full-length WT α-syn and A53T α-syn (16). In this model, 
lipofectamine-mediated transfection of recombinant fibrils leads to aggregation of the 
endogenous YFP-labeled protein that are seen as fluorescent puncta. Additionally, these 
puncta increase in size and number over time. This proliferation of aggregates over time 
is indicative of a ‘seeding’ phenomenon whereby a small amount of amyloid fibrils 
induces aggregation of the endogenous protein. First we tested the parent peptide 
segment, NACore to check its effect on seeding. α-syn was aggregated in the presence of 
molar excess of NACore (Fig. 2B). The mixture was transfected in cells and puncta 
formation was visualized and the number of puncta were counted as particles per well. As 
expected, NACore did not cause a significant reduction in puncta formation in either cell 
line. Next we aggregated 50 µM α-syn in the presence of 500 µM, 250 µM, 100 µM and 
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50 µM inhibitor corresponding to 10, 5, 2 and 1 fold excess. The mixture was then 
transfected in cells and aggregation was monitored over time for up to 3 days by 
fluorescence imaging (Fig. 2A). S37 caused a significant reduction in seeding for up to 2 
days in both WT and A53T expressing cell lines. Similar to S37, S61 (Fig 2D) also 
caused a reduction in puncta formation with maximum efficacy at 2, 5 and 10 fold excess 
in both cell lines. Aggregates formed in the presence of S62 (Fig. 2E) were also seeding 
incompetent with significantly less particles forming at all inhibitor concentrations. S71 
was tested at equimolar and sub-stoichiometric ratios and found to reduce the seeding 
potency of the aggregates (Fig. 2F). These results suggest that the inhibitors prevent 
formation of seeding competent aggregates. 
 
4. Co-transfection of α-syn fibrils with the inhibitors prevents seeding by fibrils 
in cell culture: Next, we tested the efficacy of the inhibitors to prevent seeding in the cell 
culture model (Fig. 3A). We transfected the α-syn fibrils along with the different 
inhibitors. NACore, the parent aggregating peptide did not affect the seeding potency of 
α-syn fibrils (Fig. 3B). S37 caused significant reduction in seeding in both cell lines at 
12.5 µM and 6.25 µM concentrations for up to 2 days (Fig. 3C). S61 at concentrations of 
2.5 µM and 1.25 µM caused a prolonged reduction of seeding lasting up to 6 days in WT 
α-syn cells and 2 days in A53T α-syn HEK cells (Fig. 3D). S62 was effective at 
concentrations of 12.5 µM and 6.25 µM in both cell lines (Fig. 3E). S71 was effective at 
all concentrations. Together these results suggest that inhibitors can cap fibril seeds and 
prevent their elongation. 
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5. Fibrils extracted from PD brain tissues seed in vitro and increase seeding 
potency in cell culture: Next we extracted insoluble protein aggregates from frozen 
autopsy PD brain tissues. We obtained tissues from 4 different subjects including the 
substantia nigra and frontal regions of one subject and temporal and frontal regions of 
other subjects. Using previously described protocols (17) that included precipitation with 
the ionic detergent sarkosyl, we extracted insoluble protein aggregates (Fig. 4A). All 
samples robustly seeded α-syn aggregation in vitro and in our cell culture model. In vitro 
addition of 2 % seeds increased the ThT fluorescence 4 to 10 fold (Fig. 4B, 4C, 4D) 
along with a small decrease in the lag time. The seeded samples were then transfected in 
HEK cells. Consistent with the ThT assay, all seeded samples induced rapid puncta 
formation (Fig. 4E, 4F, 4G). Thus, fibrils extracted from PD brain tissues seeds 
recombinant protein, and the aggregates formed upon seeding induce rapid puncta 
formation in cell culture.  
 
6. Inhibitors prevent seeding by PD fibrils in vitro and in cell culture: We tested 
the effect of the different inhibitors in preventing α-syn aggregation in the presence of PD 
extracted seeds. S61 and S62 were most effective showing efficacy against all seeds as 
measured by ThT fluorescence assay (Fig. 5). S71 also reduced aggregation of two 
different seeds (Fig. 5B, 5D) whereas S37 showed marginal reduction in ThT 
fluorescence (Fig. 5D). Next we tested the seeding potency of the α-syn aggregates 
formed in the presence of PD seeds and the different inhibitors (Fig. 6A). Aggregates 
formed in the presence of S71 (Fig. 6B, 6C and 6D) did not induce puncta formation in 
both WT and A53T expressing HEK cells. S61 also showed efficacy (Fig. 6C). 
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Consistent with the in vitro assay, S37 was not effective in reducing the seeding potency 
of aggregates. Together these results suggest that S61 and S71 can prevent formation of 
seeding competent fibrils. 
 
7. Inhibitors prevent seeding of PD fibrils seeded α-syn fibrils: We tested the 
efficacy of the inhibitors in preventing seeding by PD fibrils in cell culture. α-syn 
aggregates formed in the presence of PD fibrils were transfected in WT HEK cells along 
with the different inhibitors (Fig. 7A). S37 prevented puncta formation for up to 2 days 
for two different PD filaments at concentrations of 12.5 µM – 1.25 µM (Fig. 7B). Similar 
to S37, S61 also showed efficacy for up to 2 days at concentrations of 12.5 µM - 1.25 
µM, and S71 also prevented seeding at similar concentrations. These results suggest that 
inhibitors robustly prevent seeding in cell culture. 
 
Discussion:  
 
We describe a structure-based approach to halt α-syn aggregation. We hypothesized that 
the atomic structure of NACore is preserved in α-syn seeds and recruits the endogenous 
protein into a zipper conformation. Using the atomic structure of NACore, we developed 
inhibitors that hinder fibril formation and tested their efficacy in vitro and in cell culture. 
The inhibitors are optimized to cap the ends of the fibril, preventing further addition of 
monomers. We used the software Rosetta to design peptide sequences that interact 
favorably with the NACore segment. The energy function used by Rosetta takes into 
account electrostatic interactions, hydrogen bonding, Van der Waals forces, among other 
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terms to assess binding energy. Once a specific residue has been shown to produce 
favorable binding in a certain position of the designed peptide, it can be fixed and 
prevented from further design, while the rest of the sequence is further refined. We 
performed this process of fixing and redesign iteratively until an optimal set of sequences 
was identified. This rational design process allowed for computationally sampling of 
orders of magnitude more inhibitor sequences than what was experimentally feasible to 
test.  
 
To find the most effective inhibitors, nearly 100 different designs were tested empirically 
with sequential rounds of optimization on the inhibitor design. For example, we observed 
that the location of the tag on N or C terminus can affect its efficiency. Additionally, the 
type of modification added can also affect its efficacy. In our case, only a Trp substitution 
at Thr72 was effective whereas Arg substitution was not. Although the computational 
approach is not powerful enough to identify one successful design, it can narrow our 
search for candidate inhibitors, which can then be refined through rational design. 
 
The efficiency of capping inhibitors in preventing seeding was tested using a cell-based 
assay. In this system, transfection of nanomolar amounts of α-syn seeds caused 
endogenous protein aggregation. The aggregates display amyloidogenic properties - 
binding to amyloid-specific small molecules, faithfully transferred upon cell division and 
remarkable specificity (16). For example, α-syn fibrils can only seed α-syn protein into 
aggregates. Notably, in this system we do not observe acute cell death upon formation of 
aggregates with only a mild slowing of cell proliferation. Our inhibitors prevented puncta 
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formation in this system with a single administration of inhibitors effective for 2-3 days. 
It will be interesting to test if the inhibitors can prevent propagation of seeds over a long 
period of time by dosing at regular intervals of time. The cell culture seeding assay it 
does not recapitulate other features of neurodegenerative diseases, notably cellular 
toxicity and the role of neuronal and non-neuronal cell types. The promising results in the 
cell culture assay merit testing our inhibitors in other model systems. 
 
Patient-extracted fibrils differ in seeding capacity and display strain-like characteristics.  
In vitro the PD patient extracted fibrils caused dramatic increase in α-syn aggregation, 
and in cell culture model the seeded samples increased puncta formation. Notably, unlike 
previous reports where patient derived α-syn filaments seeds in cell culture, in our assays 
we did not observe seeding in cell culture (18, 19). Previous reports utilized substantia 
nigra tissues whereas we used frontal and temporal tissues, which might differ in seeding 
potency. Indeed in previous reports, fibrils extracted from different brain regions have 
been shown to differ in seeding capacity reminiscent of different strains (18). 
Furthermore, the different inhibitors varied in efficiency against different seeds. For 
example, S61 was effective against seeds A and B only whereas S71 was effective 
against seeds B and D. Recently, an NMR structure of full length α-syn fibrils was 
reported in which the NACore segment was not found in an extended zipper 
conformation although the segment 68-78 is found in the core of the fibril (4). It is 
conceivable that the NMR structure and the steric zipper structure are different 
polymorphs. In the absence of a diagnostic method to identify different polymorphs in 
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human subjects, theoretically a cocktail of different inhibitors targeting different 
polymorphs could be useful. 
 
In summary, we used a combination of computational methods and rational design to 
develop a line of inhibitors targeted at preventing the spread of α-syn aggregates. Our 
approach was only made possible by the determination of the atomic structure of the core 
of α-syn amyloid fibrils, and this approach can be adopted for other diseases where 
seeding plays a role in disease progression. 
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Materials and methods: 
 
α-synuclein purification: The α-synuclein construct was transformed into Escherichia 
coli expression cell line BL21 (DE3) gold (Agilent Technologies). For expression, 10 ml 
LB + Amp (100 µg/mL) was inoculated from transformed colonies and grown overnight. 
30 ml of starting culture was added to a 2 L flask containing 1 L LB + Amp (100 µg/mL) 
and grown for 3 hours at 37 °C to OD600 = 0.6. IPTG was then added to 0.5 mM to 
induce protein expression, which continued for an additional 3 hours. The bacterial pellet 
was collected by centrifugation at 4000 rpm for 10 mins. Cell pellet was resuspended in 
15 mL/L pellet lysis buffer  (100 mM Tris- HCl pH 8.0, 1 mM EDTA pH 8.0) and lysed 
by sonication. Crude cell lysate was clarified by centrifugation at 15,000g for 30 min at 4 
°C. 10 mg/ml Streptomycin was added to the supernantant and stirred on ice for 30 mins 
followed by centrifugation at 15000 rpm for 30 mins. Protein was then purified by 
ammonium sulfate precipitation by adding 0.22 g.ml ammonium sulfate and stirred on ice 
for 30 mins followed by centrifugation at 15000 rpm for 30 mins. The supernatant was 
discarded and the pellet re-suspended in 12 mL/L pellet of 20 mM Tris pH 8.0. The 
solution was then dialyzed against 4 L 20 mM tris pH 8.0 overnight to remove residual 
ammonium sulfate. Next day the protein was purified by HiPrep Q HP 16/10 column (GE 
Healthcare) using buffer A (20mM Tris pH 8.0) and buffer B (20mM Tris pH 8.0; 0.5M 
NaCl) using a gradient from 0-100% buffer B over 100 mL. Fractions containing protein 
were collected and pooled and injected on a preparative size exclusion silica G3000 
column (Tosoh Bioscience). The column buffer comprised 0.1 M sodium sulfate, 25 mM 
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sodium phosphate, and 1 mM sodium azide, pH 6.5. Protein fractions were collected and 
concentration measured by Pierce BCA protein assay (Thermo #23225). 
 
Inhibitor synthesis: Inhibitors were commercially obtained from Genscript Inc. at 
greater than 98% purity and solubilized in 100% DMSO at 10 mM concentration. 
Solublized inhibitors were filtered with 0.1 µM filter and stored at -20 °C in 20 µL 
aliquots until further use.  
 
Thioflavin T assays: Fibril formation assays were performed with 50 µM protein 
concentration in conditions identical to those used for aggregating proteins for seeding 
assay, but with the addition of ThT. All assays were carried out in black Nunc 96-well 
optical bottom plates (Thermo Scientific). Plates were agitated at 600 rpm in 3-mm 
rotation diameter in a Varioskan microplate reader (Thermo) at 37 °C. Fluorescence 
measurements were recorded every 30 mins using λex = 444 nm, λem = 482 nm, with an 
integration time of 200 µs. 
 
Aggregation assays: Purified α-synuclein was dialyzed in 0.1 M sodium sulfate, 25 mM 
sodium phosphate and aggregated by shaking in Torrey Pine shakers at 50 µM at 37 °C at 
speed 9 for 5-6 days. 
 
Extraction of sarkosyl insoluble protein filaments from PD human brain tissues: 
Human frozen brain tissues were obtained from UCLA Brain Tumor Translational 
Resource (BTTR). Sarkosyl insoluble protein was extracted using previously described 
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protocols. Briefly, frozen tissue was homogenized in ice cold PBS using a dounce 
homogenizer at 200 mg/mL. The homogenate was then diluted in buffer A (10mM Tris 
7.4, 800mM NaCl, 1mM EGTA, 10% Sucrose) to 50 mg/mL in total volume of 1 mL and 
centrifuged at 20,700 g for 20 min at 4°C. The supernatant was collected in an 
ultracentrifuge tube and pellet was resuspended in 0.5 mL  buffer A followed by 
centrifugation at 20700 g for 20 mins at 4 °C. The supernatants pooled together. 150 µl 
10% sarkosyl (w/v) in Millipore water was then added and incubated for 1 h at room 
temperature on flat rotating shaker at 700 rpm. The solution was then centrifuged at 
100,000 g for 1 h at 4°C using SW 55 Rotor (Beckman Coulter). The supernatanat was 
discarded and pellet was washed with 5 mL Buffer A and centrifuged at 100,000 g for 20 
mins at 4 °C. The pellet was resuspended in 100 µl 50 mM Tris pH7.4 
 
HEK 293T cell culture: HEK293T cells that stably express YFP labeled WT α-syn and 
A53T α-syn were a generous gift from Dr. Marc Diamond. Cells were grown in 
Dulbecco’s modified Eagle’s medium (Gibco) supplemented with 10% fetal bovine 
serum (HyClone), 1% penicillin/streptomycin (Gibco), and 1% glutamax (Gibco) in a 
humidified incubator in 37°C, 5% CO2. 
 
Seeding in HEK293T cells: 10,000 cells in 90 µL media were plated in 96 well black 
wall plate (Cat #3660) and allowed to adhere overnight. α-syn was transfected at a final 
monomer concentration of 125 nM. Lipofectamine 2000 was diluted in OptiMEM media 
(2.5 + 17.5 µL) and incubated at room temperautre for 5 mins. Protein aggregates were 
diluted in OptiMEM media (1:20) and sonicated in a water bath sonicator for 3 mins at 
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low pulse.  Diluted lipofectamine and protein samples were then mixed 1:1 and incubated 
at room temperature for 20 mins and thereafter 10 µL was added to each well. All 
samples are added in triplicates and experiments were repeated a minimum of two times. 
For co-transfection of α-syn fibrils with inhibitors, the fibrils and inhibitors were diluted 
in OptiMEM and incubated for 3 hours followed by sonication.  
 
Measurement of intracellular puncta in cells: Puncta formation and cell growth was 
measured using Celigo Imaging Cell Cytometer allowing for unbiased measurement. 
Wells were imaged using fluorescent GFP channel and confluence was measured using 
Celigo analysis software. Images of entire well were taken and particles counted by 
ImageJ by particle analysis. Same settings were used to analyze wells of one plate at all 
days. Total particles counted in each well were normalized against the confluence and 
reported as particles per well.  
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Figure Legend 
Fig. 1: Design of α-syn seeding inhibitors. (A) Structure based design of α-syn 
aggregation inhibitors. Structure of NACore is composed of two self-complementary β-
sheets forming steric zipper. Three types of inhibitors (maroon, orange and cyan) were 
identified that bind one or both ends. (B) Binding energies of the different inhibitors 
calculated by Rossetta show S37 and S62 bind both interfaces while S71 is only predicted 
to bind one interface. Shape complementarity of all three inhibitors is high. (C) 
Thioflavin T assay to measure α-syn aggregation and the effect of inhibitors. 50 µM α-
syn and inhibitors at 5 fold molar excess were added.  
 
Fig. 2: α-syn aggregates formed in the presence of inhibitors are not seeding 
competent. (A) Experimental design of cell culture seeding assay. α-syn was aggregated 
in the presence of inhibitors and the mixture was transfected in HEK293 cells expressing 
YFP labeled WT α-syn or A53T α-syn (green). Upon transfection endogenous α-syn 
formed fluorescent puncta (red)  (B) NACore does not affect seeding capacity of α-syn 
fibrils. (C,D,E)  50 µM α-syn aggregated in 10, 5, 2 and 1 fold excess of S37, S61 and 
S62 was not seeding competent as measured by counting total number of particles formed 
per well in both WT and A53T expressing cells. (F) 50 µM α-syn aggregated in excess of 
S71 was not seeding competent as measured by counting total number of particles formed 
per well in both WT and A53T expressing cells. Results shown as Mean + SD (n=3). 
Statistical significance was analyzed by two way ANOVA. 
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Fig. 3: Inhibitors prevent seeding in cell culture. (A) Experimental design of cell 
culture seeding assay. 125 nM recombinant α-syn fibrils were transfected with different 
amounts of inhibitors and aggregation monitored over time. (B) NACore does not affect 
seeding capacity (C, D, E, F) S37, S61, S62 and S71 reduce seeding capacity of α-syn. 
All data reported as particles counted per well and normalized to particles counted in 
buffer treated wells. Results shown as Mean + SD (n=3). Statistical significance was 
analyzed by two way ANOVA. 
 
Fig. 4: PD brain tissue extracted filaments seed α-syn aggregation in vitro and in cell 
culture. (A) Protocol for extraction of sarkosyl insoluble protein filaments from PD brain 
tissues. (B,C,D) 2% seeds from 3 different subjects induce rapid α-syn aggregation with 
4-10 fold increase in ThT fluorescence. (E,F,G) α-syn seeded by filaments from PD 
subjects induce more particles than α-syn alone. All data reported as particles counted per 
well and normalized to particles counted in buffer treated wells. Results shown as Mean 
+ SD (n=3). Statistical significance was analyzed by two way ANOVA. 
 
Fig. 5: Inhibitors prevent seeding by PD tissue extracted filaments. Filaments from 4 
different subjects were tested for seeding α-syn aggregation and monitored by ThT assay. 
S61 and S62 were effective against all seeds that were tested. S71 was effective against 
seeds B and D.  
 
Fig. 6: α-syn fibrils formed in the presence of PD filament seeds and inhibitors are 
not seeding competent. (A) Experimental design of cell culture seeding assay (B, C, D) 
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Inhibitors were tested for inhibition of seeding by three different PD brain extracted 
tissues. S71 was effective against all three seeds while S61 was effective against Seeds B. 
All data reported as particles counted in each well normalized to the particles counted in 
buffer treated wells. Results shown as Mean + SD (n=3). Statistical significance was 
analyzed by two way ANOVA. 
 
Fig. 7: Inhibitors reduce seeding by PD filament seeded α-syn fibrils in cell culture. 
(A) Experimental design of cell culture seeding assay. (B,C,D)  α-syn fibrils formed in 
the presence of two different PD related filaments were transfected in YFP- α-syn HEK 
cells and fluorescence measured thereafter for up to 6 days. S37 prevented seeding at 
concentrations of 12.5 µM - 1.25 µM. S61 prevented seeding with a pronounced effect on 
Day 2. S71 reduced seeding at concentrations of 6.25 µM. All data reported as number of 
particles counted per well normalized to particles counted on Day 0 before transfection. 
Results shown as Mean + SD (n=3). Statistical significance was analyzed by two-way 
ANOVA. 
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Fig. 7 
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Table 1: Clinical Information of human tissues used in this study 
 
Specimen 
ID 
Brain 
Region 
Age Sex Braak 
Stage 
Clinical Diagnosis 
(A) Parietal 94 F V Parkinson’s Disease with 
chances of AD 
 (B) Left Frontal 89 F NA Parkinson’s disease 
 (C) Right 
Temporal 
75 M II Parkinson’s disease with 
chances of AD 
 (D) SN 78 M NA Parkinson’s Disease 
 (E) Right Frontal 89 F IV Parkinson’s disease with 
chances of AD 
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